Rolle von endothelialen Cytochrom-P450-Epoxygenasen in der Regulation der Angiogenese by Webler, Anke Christiane Gisela
 
Role of endothelial Cytochrome P450 epoxygenases in the 
regulation of angiogenesis 
 
 
 
Dissertation 
zur Erlangung des Doktorgrades 
der Naturwissenschaften 
 
 
 
vorgelegt  beim Fachbereich 
Biochemie, Chemie und Pharmazie 
der Goethe-Universität 
in Frankfurt am Main 
 
 
 
 
von 
Anke Christiane Gisela Webler 
aus Mainz 
 
Frankfurt 2008 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
vom Fachbereich Biochemie, Chemie und Pharmazie 
der Goethe-Universität als Dissertation angenommen 
 
 
 
 
Dekan:  Prof. Dr. Harald Schwalbe 
Gutachter:  Prof. Dr. Ingrid Fleming 
Prof. Dr. Theodor Dingermann 
 
 
Datum der Disputation: 
 
 
  
   
Part of this work has been published in the following papers: 
 
Webler, A.C., Popp R., Korff T., Michaelis U.R., Urbich C., Busse R., Fleming I., 2008. 
Cytochrome P450 2C9-induced angiogenesis is dependent on EphB4. Arterioscler. 
Thromb. Vasc. Biol. 28(6):1123-9 
 
Webler, A.C., Michaelis U.R., Popp R., Barbosa-Sicard E., Murugan A., Falck J.R., 
Fisslthaler B.,  Fleming I., 2008. Epoxyeicosatrienoic acids are part of the VEGF-
activated signaling cascade leading to angiogenesis. Am J Physiol Cell Physiol. In 
revision. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Paul & my parents  
   
Table of contents 
 
1.  Introduction ............................................................................................................1 
1.1  Cytochrome P450 enzymes and CYP-derived metabolites of arachidonic acid 1 
1.2  Epoxyeicosatrienoic acids.................................................................................6 
1.3  Expression of CYP-derived epoxyeicosatrienoic acids in vitro and in vivo........7 
1.4  Vasculogenesis and angiogenesis....................................................................8 
1.5  Angiogenesis in health and disease................................................................12 
1.6  EETs, proliferation and angiogenesis..............................................................14 
1.7  Growth factors acting via endothelial cell-specific receptor tyrosine kinases ..15 
1.7.1  Vascular endothelial growth factor (VEGF)..............................................16 
1.7.2  EphB4 ......................................................................................................17 
1.8  Aim of the study...............................................................................................18 
 
2.  Materials and Methods.........................................................................................20 
2.1  Materials..........................................................................................................20 
2.2  Cell culture ......................................................................................................21 
2.3  Transfection of endothelial cells......................................................................23 
2.4  Adenoviral infection of endothelial cells...........................................................23 
2.5  EET measurements by LC-MS/MS .................................................................24 
2.6  Transfection with antisense oligonucleotides ..................................................24 
2.7  Downregulation by RNA interference..............................................................25 
2.8  Reporter gene assay.......................................................................................25 
2.9  Protein isolation...............................................................................................26 
2.10  Immunoprecipitation........................................................................................27 
2.11  Immunoblotting................................................................................................27 
2.12  RNA-Isolation and reverse transcriptase polymerase chain reaction (RT-PCR) .
 ........................................................................................................................28 
2.13  In vitro angiogenesis assays ...........................................................................29 
2.13.1  Fibrin gel: .................................................................................................29 
2.13.2  Spheroid assay: .......................................................................................29 
2.14  In vivo angiogenesis assays............................................................................30 
2.15  Immunohistochemistry ....................................................................................32  
   
2.16  Contrast enhanced sonography ......................................................................33 
2.17  Statistical analysis...........................................................................................33 
 
3.  Results ..................................................................................................................34 
3.1  Effect of CYP2C9 on EphB4 expression.........................................................34 
3.2  Role of CYP2C9-induced EphB4 expression in angiogenesis in vitro.............37 
3.3  Role of the PI3K signalling pathway in CYP2C-induced angiogenesis............38 
3.4  Role of EETs in cell proliferation and angiogenesis in situ..............................40 
3.5  Role of CYP-induced EphB4 expression in vivo..............................................42 
3.6  Effect of VEGF on CYP2C expression............................................................45 
3.7  Role of the AMP-activated protein kinase (AMPK) in CYP2C-induced 
angiogenesis..............................................................................................................47 
3.8  Role of VEGF-induced CYP2C expression in cell proliferation and 
angiogenesis in vitro ..................................................................................................50 
3.9  Role of VEGF-induced CYP-derived EETs in angiogenesis in vivo ................53 
 
4.  Discussion............................................................................................................58 
4.1  Role of EphB4 and VEGF in CYP2C-induced angiogenesis...........................58 
4.2  Role of EETs in vessel maturation ..................................................................66 
4.3  The putative EET-receptor and the role of endogenous EET production and 
exogenous EET application in angiogenesis..............................................................69 
4.4  Relevance of this study...................................................................................71 
 
5.  Summary...............................................................................................................74 
 
6.  Zusammenfassung...............................................................................................76 
 
7.  Reference list........................................................................................................81 
 
8.  Abbreviations .......................................................................................................94 
 
9.  Acknowledgments................................................................................................96 Introduction 
 
  1
1. Introduction 
 
1.1 Cytochrome P450 enzymes and CYP-derived metabolites of 
arachidonic acid 
 
Cytochrome P450 (CYP) enzymes are membrane-bound heme enzymes named for the 
absorption band at 450 nm of their carbon
 monoxide (CO)-band or complexed form.  
They are involved in a number
 of vital processes including carcinogenesis and drug 
metabolism
 as well as the biosynthesis of steroids or lipids. 
The most common reaction catalysed by CYP enzymes is a monooxygenase reaction, 
e.g. insertion of one atom of oxygen into a substrate while the other oxygen atom is 
reduced to water (Figure 1).  The heme-containing enzymes are part of a multi-enzyme 
complex that also consists of cytochrom b5 and a NADPH cytochrome reductase and 
have a variety of functions.  Some CYPs are substrate specific, but most can 
metabolize multiple substrates, and many can catalyze multiple reactions, which 
accounts for their central importance in metabolizing an extremely large number of 
endogenous and exogenous molecules.  Even though most of the CYP enzymes are 
expressed in the liver where their substrates include drugs and toxic compounds as well 
as metabolic products such as bilirubin, they are also present in many other tissues of 
the body including the mucosa of the gastrointestinal tract, and play important roles in 
hormone synthesis and breakdown (including estrogen and testosterone synthesis and 
metabolism), cholesterol synthesis, and vitamin D metabolism. 
CYP enzymes have been described in a number of different contexts since their 
discovery at the beginning of the 1960’s and were subdivided into families and 
subfamilies according to their homology.  At 55% homology enzymes are classified as 
the same subfamily that is indicated by a letter.  Starting at a homology of 40% 
enzymes are classified as a family that is indicated by an Arabic numeral.   
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Figure 1.  The catalytic cycle of CYP monoxygenases.  At the start of the reaction cycle the substrate 
binds to the active centre close to the ferric ion of the central heme group (A).  The ferric ion is reduced to 
the ferrous ion via electron transfer by the CYP NADPH reductase (B) in order to be in a state for 
molecular oxygen to be attached (C).  After this oxidation of the substrate the dioxygen bond is 
destabilised by attachment of a second reductase-derived electron (D) and oxygen is separated in form of 
a water molecule (E).  After water formation a number of instable intermediate products are formed (F-G) 
resulting in the separation of the oxidised substrate.  From Zangar et al., 2004. 
 
CYP-derived epoxides of arachidonic acid, such as 5,6-, 8,9, and 11,12-
epoxyeicosatrienoic acid (EET) that are responsible for the cyclooxygenase-
independent renal vasodilatation in rats (Pomposiello et al., 2003), play an important 
role in the regulation of vascular tone and homeostasis (for review see Fleming, 2001)) 
and have originally been linked to vascular smooth muscle cell hyperpolarisation and 
relaxation (Rosolowsky and Campbell, 1993; Campbell et al., 1996).  These ecosanoids 
are also important intracellular signalling molecules that modulate much more than 
membrane potential.  Multiple CYP enzymes metabolize arachidonic acid to EETs in a 
number of species and tissues (Table 1).   Introduction 
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Table 1. Formation of EETs from arachidonic acid by different CYP isoforms.  From Roman, 2002 
 
Arachidonic acid is a polyunsaturated fatty acid that is present in the phospholipids of 
membranes of cells  and is freed from this phospholipid molecule via cleavage by the 
enzyme phospholipase A2.  Arachidonic acid can be metabolised via three main 
pathways, namely via cyclooxygenases (COX), lipoxygenases (LOX) and CYP 
epoxygenases (Figure 2) to generate biologically active fatty acid metabolites 
(eicosanoids).   
In addition to its role in the metabolism of xenobiotics, the arachidonic acid pathway was 
of interest for vascular biologists because of its effect on vascular function (Aiken, 
1974); initially mainly on renal physiology (McGiff et al., 1970).  Furthermore, COX-2 
was shown to reduce angiogenesis and specific inhibitors, e.g. celecoxib, are effective 
in cancer treatments (Kawamori et al., 1998). Likewise, LOX levels are upregulated in 
certain cancers such as prostate carcinoma (Gao et al., 1995).  More recently CYP Introduction 
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enzymes have also been reported to play a role in the pathogenesis of a variety of 
human
 cancers by for example promoting the neoplastic
 cellular phenotype (Jiang et al., 
2005). 
CYP epoxygenases produce different regio- and stereoisomeric epoxides (5,6-; 8,9-; 
11,12- and 14,15  epoxyeicosatrienoic acid, EET), whereas the ratio of EET-isomers 
produced is dependent on the specific CYP isomer studied.  For example, in the 
endothelium CYP2C9 generates 14,15-EET, 11,12-EET and 8,9-EET at a ratio of 
2,3:100:0,5.  Despite its 80% homology the CYP2C8 isomer generates substantial 
amounts of 11,12-EET and 14,15-EET, but hardly any 8,9-EET (Daikh et al., 1994).  In 
contrast to the epoxygenases, the ω-hydroxylases, metabolise arachidonic acid to 
hydroxyeicosatrienoic acids (HETEs) (Guengerich et al., 1995).  Furthermore, there are 
some enzymes e.g. CYP 4A2 and 4A3, but also CYP2C9 that generate 11,12-EETs as 
well as 20-HETE (Nguyen et al., 1999).  Of the CYP isoforms expressed in human ω-
hydroxylases of the 4A family are primarily found in smooth muscle cells (Roman, 
2002), whereas CYP2C8, CYP2C9 and CYP2J2 are mainly expressed in the 
endothelium (Fisslthaler et al., 1999).  While  CYP2C9 expression appears to be 
predominant in the endothelium of aorta and coronary arteries (Delozier et al., 2007), 
CYP2C8 and CYP2J2 are mainly found in the human heart.   
Once synthesised EETs can be incorporated into phospholipids, especially into 
phosphatidylcholine and phosphotidylinositol (Capdevila et al., 1981; VanRollins et al., 
1993).  The physiological significance of this process is not yet understood, but some 
observations hint at the possibility that these lipids may be intracellular EET stores that 
can release the metabolites independently if required (Weintraub et al., 1997).  On the 
other hand, EETs are mainly metabolised by the soluble epoxide hydrolase (sEH) as 
well as a microsomal form of the enzyme (mEH) to generate the biologically less active 
dihydroxyeicosatrienoic acids (DHETs).  Only 5,6-EETs are chemically less stable and 
preferentially metabolised by COX ( Oliw et al., 1981; Chacos et al., 1983). 
Originally DHETs were assumed to be simply biologically inactive metabolites.   
However, recently several groups have demonstrated that they have vasorelaxating 
properties in porcine coronary arteries and other species (Oltman et al., 1998), and are 
also able to selectively activate the peroxisome-proliferator activated receptor PPARα 
(Fang et al., 2006). 
While the sEH is the biologically most important EET regulating enzyme, EETs can be 
transformed either to shorter (via β-oxidation) or longer (via C2-attachment) derivatives.  Introduction 
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However, these alternative metabolic routes do not seem to be be able to completely 
compensate for the loss of sEH activity as EET levels are chronically increased in sEH-
deficient (sEH-/-) animals (Sinal et al., 2000). 
20-HETE as well as the EETs play an important role in the regulation of vascular tone.  
20-HETE is a potent vasoconstrictor produced in vascular smooth muscle cells that 
depolarizes vascular smooth muscle cells by attenuating the open probability of Ca
2+-
activated K
+-channels (Miyata and Roman, 2005).  20-HETE also plays a role in 
angiogenesis, and is reported to be a component of the FGF-2-activated signalling 
pathway.  It has for example been shown that FGF-2 is able to activate phospholipase 
A2 resulting in arachidonic acid production and subsequent 20-HETE release by CYP4A 
(Sa et al., 1995).  In vivo, in the corneal neovascularisation model, CYP4A inhibitors 
have been shown to abrogate the angiogenic response to VEGF, FGF-2 and EGF 
(Chen et al., 2005). 
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Figure 2.  The arachidonic acid metabolism.  Arachidonic acid metabolism by CYP epoxygenases 
results in the formation of different regioisomers of epoxyeicosatrienoic acids and hydroxyeicosatetranoic 
acids.  Arachidonic aid is metabolised by three main pathways: via COX, LOX and CYP ω/ω-
hydroxylases and epoxygenases.  CYP epoxygenases generate different regioisomers of 
epoxyeicosatrienoic acid (5,6-, 8,9-, 11,12-, 14,15-EETs) that can be further metabolised by cyclo-
oxygenases (5,6-EET), via β-oxidation (8,9-, and 14,15-EETs) or by soluble epoxide hydrolase (11,12-
EET).  From Fleming, 2001. 
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1.2 Epoxyeicosatrienoic  acids 
 
Interest in EETs and their vascular actions was originally linked to their identification as 
an endothelium derived hyperpolarizing factor (EDHF).  Indeed, EETs stimulate
 the 
opening of calcium-activated potassium channels (K
+
Ca) (Hu and Kim, 1993; Campbell 
et al., 1996) and the hyperpolarisation of 
 endothelial cells in addition to activating the 
Na
+-K
+-ATPase. This results in an endothelium-dependent
 hyperpolarisation of smooth 
muscle cells, which may also involve direct electrical coupling through myo-endothelial 
junctions especially in small arteries
 and/or the accumulation of K
+ ions in the sub-
endothelial space ( Edwards et al., 1998; Busse et al., 2002).  Exogenously applied 
EETs activate iberiotoxin-sensitive, large-conductance calcium-sensitive K
+ channels 
(BKCa).  However, the EDHF-mediated relaxation of porcine coronary arteries that 
 is 
sensitive to the CYP2C9 inhibitor sulfaphenazole and that
  can be attenuated by 
antisense oligonucleotides directed against
  CYP2C, is insensitive to iberiotoxin (a 
selective inhibitor of BKCa-channels), but sensitive to charybdotoxin
  (a nonselective 
inhibitor of BKCa  and  IKCa  channels) and apamin (a nonspecific inhibitor of SKCa) 
(Fisslthaler et al., 1999).  This suggests on the one hand that the role of EETs in the 
EDHF phenomenon
 may not simply be related to the activation of BKCa channels.  On 
the other hand the EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) 
attenuates
 the bradykinin-induced hyperpolarisation of native porcine coronary
 artery 
endothelial cells and this has been associated with the activation of endothelial 
intermediate- and small-conductance Ca
2+-sensitive K
+ channels (SKCa and IKCa) 
channels (Weston et al., 2005).  
Physiologically relevant concentrations of nitric oxide (NO) attenuate EDHF-mediated 
dilatations via a decreased formation of this hyperpolarizing factor (Bauersachs et al., 
1996).  It is however known that NO inhibits CYP and this would not only explain the 
reduced EDHF answer in the presence of NO, but also the observation that in vessels 
that generate NO the EET-mediated hyperpolarisation is only of minor importance under 
physiological conditions.  In contrast under pathophysiological conditions, such as 
endothelial dysfunction where the bioavailability of NO is reduced, EDHF/EET may 
represent important endogenous signalling mechanisms to compensate for loss of NO.   
Keeping in mind the effects of EDHF/EETs on vascular tone, the pharmacological 
inhibition of the sEH is a potential approach to enhance EET-mediated vascular Introduction 
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protection and may be useful as a treatment for coronary artery disease and 
hypertension. 
EETs elicit a number of other effects that can not be attributed to their role as an EDHF 
and it is now generally accepted that arachidonic acid epoxides are much more than 
vasodilators/vasoconstrictors.  In fact, they induce a large number of effects other than 
those associated with K
+
Ca channels suggesting that the intracellular second messenger 
role of EETs may be their most important function.  However, the signalling pathways 
that are involved seem to be largely dependent on species, the type of endothelium and 
the regioisomers that are involved.  Furthermore, it has been shown that certain 
structural requirements, such as for example the location of the double bond, are 
essential for the mechanism of action of the molecule (Falck et al., 2003).  In human 
umbilical vein endothelial cells (HUVECs) in particular 11,12- and 14,15-EETs activate 
several signalling molecules including tyrosine kinases and phosphatases (Fleming et 
al., 2001a), the p38 mitogen-activated protein (MAP) kinase, extracellular regulated 
protein kinase 1 and 2 (ERK1/2), MAP kinase phosphatases and inhibit other signalling 
molecules such as c-Jun N-terminal kinase.  Furthermore EETs affect endothelial cell 
proliferation and angiogenesis, an effect at least partly attributable to transactivation of 
the epidermal growth factor (EGF) receptor (Chen et al., 1999; Michaelis et al., 2003).  
In murine pulmonary endothelial cells the responses reported are a bit more diverse, 
and while 5,6- and 11,12-EET stimulate proliferation through a phosphatidylinositol-3 
kinase (PI3K)-pathway, the effects mediated by 8,9- and 11,12-EET are dependent on 
the p38 MAP kinase pathway (Pozzi et al., 2005).   
 
 
1.3 Expression  of  CYP-derived epoxyeicosatrienoic acids in vitro and 
in vivo 
 
As mentioned above the different CYP-derived EET-regioisomers have for a number of 
years been widely accepted to play a role in vascular smooth muscle cell 
hyperpolarisation and dilatation, but their role as second messengers that modulate a 
variety of processes other than membrane potential have been overlooked.  Indeed 
their role in angiogenesis, which will be elucidated in more detail later on in the text and 
in the course of this study, has been largely overlooked.  One of the main reasons for Introduction 
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this has certainly been a lack of appropriate experimental tools and strategies that take 
into account the rather labile nature of the enzymes in culture.  Thus, although CYP 
epoxygenases can be detected without problems in native tissues, expression levels 
rapidly decrease following cell isolation.  As a matter of fact, porcine coronary 
endothelial cells that clearly express CYP2C in situ, rapidly downregulate protein 
expression and  48 hours after cell isolation, the RNA of the enzyme is only detectable 
by RT-PCR (Fisslthaler et al., 2000a).  Therefore, under static cell culture conditions, 
i.e. lacking the hemodynamic stimuli to which the native endothelium is continually 
exposed, transcriptional processes seem to play an important role in the regulation of 
CYP2C expression levels and may account for the labile nature of proteins.  This also 
fits well with observations that physiological stimuli, such as cyclic stress (Fisslthaler et 
al., 2001) result in a significant increase in CYP2C protein expression levels as well as 
in endothelial EET production.   
Consequently, in practice when investigating the consequences of CYP2C activation in 
cells cultured the enzyme needs to be upregulated.  This can be achieved by the 
application of shear stress or cyclic stretch or by incubation with pharmacological 
stimuli, the so called ‘CYP-inducers’ such as nifedipine and cortisol (Fisslthaler et al., 
2000b ; Bauersachs et al., 2002).  Of course one further possibility is to overexpress the 
enzyme of interest using either a transfection or adenoviral approach. 
 
 
1.4  Vasculogenesis and angiogenesis 
 
The cardiovascular system is the first organ system to develop and reach a functional 
state in the vertebrate embryo.  The initial steps consist of ‘vasculogenesis’, which 
basically means the in situ differentiation of endothelial cell precursors, the angioblasts, 
from the hemangioblasts to form a network of primitive tubules (Risau and Flamme, 
1995).  The juvenile vascular plexus develops from the primary capillary plexus by 
proliferation of endothelial cells, subsequent pruning and reorganization of endothelial 
cells in the process called ‘sprouting angiogenesis’ (Risau, 1997) to form more mature 
appearing vascular patterns seen in the adult organism (Figure 3 ).  This sprouting of 
new vessel segments follows a well-defined program; degradation of basement 
membrane, endothelial cell proliferation, formation of sprouts of endothelial cells Introduction 
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connecting a neighbouring vessel and restructuring of the sprout into a lumen lined by 
endothelial cells and integrated in the vascular network.   
 
 
 
Figure 3.  The formation of the vascular network.  Hemangioblasts in the embryo differentiate into 
hematopietic stem cells and endothelial progenitors that then differentiate to arterial and venous 
endothelial cells and assemble in a primitive capillary plexus (vasculogenesis).  Vessels then sprout and 
become stabilized by smooth muscle cells that differentiate from their progenitors.  Furthermore 
hematopoietic stem cells contribute to angiogenesis directly and indirectly, by differentiating to leukocytes 
or platelets.  Appreviations: Shh, Sonic hedgehog; Grdl, Gridlock; M , macrophage; AML, acute myeloid 
leukemia; Scl, stem cell leukemia.  From Carmeliet, 2003.   
 
Alternatively during ‘intussusceptive angiogenesis’, also known as ‘splitting 
angiogenesis’, the key event is the formation of transluminal tissue pillars.  The process 
begins with the protrusion of opposing capillary walls into the vessel lumen (Figure 4).  
After establishing an interendothelial contact, the endothelial bilayer and the basal 
membranes are perforated centrally and the newly formed pillar increases in girth after 
being invaded by fibroblasts and pericytes.  The capillary wall expands to the lumen to 
split a single vessel in two (Kamei et al., 2006; Bianco et al., 2007).   
Sprouting angiogenesis has great advantages, because it is invasive and can therefore 
bridge vascular gaps as for example required during wound healing.  On the other hand 
intussuseption is much faster, appears to be metabolically and energetically more Introduction 
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effective and represents a unique way to expand and increase the complexity of the 
vascular tree (for review see Burri et al., 2004). 
 
Our view of processes that contribute to the formation of new vessels in adult animals 
and humans has also been modified by the realisation that the incorporation of bone-
marrow-derived endothelial precursor cells contributes to vessel growth, a process that 
complements the sprouting of resident endothelial cells (Asahara et al., 1997).   
In the adult, development of the vasculature is essential for tissue repair and 
reproductive functions such as control of ovulation and menstruation.  On the other 
hand uncontroled angiogenesis or abnormal vascular remodelling contributes to the 
pathologenesis of disorders such as cancer, arthritis and psoriasis, but also obesity, 
asthma and infectious diseases.  The formation of vessels is a complex process, 
requiring a finely tuned balance between numerous stimulatory and inhibitory signals, 
such as integrins, angiopoietins, chemokines, junctional molecules, oxygen sensors, 
endogenous inhibitors and many others (Carmeliet, 2003).   
The latter phase of vascular development also involves the sprouting and penetration of 
vessels into previously avascular regions of the embryo, and also the differential 
Figure 4.  Endothelial tubes assemble in vivo.  A and B, time-lapse images and schematic view of the 
fusion process of intracellular vacuoles of two endothelial cells to form a single luminal space.  C, 
cytoplasm of cultured endothelial cells is labelled in green and red.  Intercellular fusion process is not 
accompanied by cytoplasmatic mixing which indicates that the formation of a common luminal space 
occurs by exocytosis of intracellular vacuoles into junctional spaces between two neighbouring cells. 
From Kamei et al., 2006 Introduction 
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recruitment of associated supporting cells such as pericytes, as well as fibroblasts to 
different segments of the vasculature.  These interactions between endothelial cells and 
mural cells (pericytes and vascular smooth muscle cells) in the blood vessel have 
recently attracted a great deal of attention as central processes in the regulation of 
vascular formation, stabilization, remodelling and function.  Failure of these interactions 
between the two cell types results in severe and often lethal cardiovascular defects in 
numerous genetic mouse models.  Therefore, establishment of a functional vascular 
network requires that nascent vessels mature into durable vessels.  Insufficient 
recruitment of mural cells would result in exaggerated endothelial cell growth, 
permeability, fragility, subsequent vessel enlargement, bleeding and impaired perfusion.  
The absence of arteriogenic factors results in naked, leaky vessels that are not 
perfusable and therefore not subject to flow which ultimately results in vessel regression 
(Figure 5).  
 
 
Figure 5.  The initial phase of vascular development involves formation of endothelial cell tubes.  
Upper panel: vessel maturation and subsequent stabilisation requires a mix of angio- and arteriogenic 
factors for a sufficient duration.  As result endothelial cells can tighten up and become firstly covered by 
smooth muscle cells (SMC) and extracellular matrix (ECM) and then maintained and further stabilised by 
flow.  Lower panel: as a consequence of insufficient angio- and arteriogenic factors (e.g. VEGF, PIGF, 
And-1, PDGF) and abudent inhibitors (i.e. TSP, IFN, Ang-2) Endothelial tubes remain naked and leaky.  
Those fragile structures are easily ruptured and bleed which leads to reduced flow and results in vessel 
regression.  From Carmeliet, 2003.   
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1.5  Angiogenesis in health and disease 
 
Excessive, insufficient or abnormal angiogenesis directly contribute to numerous 
malignant, ischemic, inflammatory, infectious and immune disorders.  Mammalian cells 
are always located within 100 to 200 µm of blood vessels and multicellular structures 
such as for example tumours must recruit new blood vessels to survive.  The proximity 
is also crucial for tumour survival and growth as without the supply of sufficient nutrients 
and oxygen via the blood stream tumours are not able to grow beyond a certain point or 
to form metastases.  This implies that in various diseases, especially cancer, the tumour 
strives to optimise its blood supply and the balance of pro-and antiangiogenic molecules 
is derailed.  The observation that angiogenesis increasingly occurs around tumours was 
made over 100 years ago by Goldman, but it took until 1971 for Folkman to propose 
that tumour growth and metastasis are angiogenesis-dependent and that blocking 
vessel growth is a possible strategy to arrest tumour growth.  Leading on from those 
findings, Gullino showed that cells in pre-cancerous tissue acquire angiogenic capacity 
on their way to become cancerous (Gullino, 1978) and that this might be the basis for a 
successful cancer strategy.  Since then it has become widely accepted that the 
‘angiogenic switch’ is ‘off’ when the pro-angiogenic molecules are balanced by the anti-
angiogenic molecules and a number of signals have been identified that trigger this 
switch.  It is well established that there are a number of molecular players involved in 
these mechanisms of vascular growth (Carmeliet, 2000) such as VEGF (Figure 6). 
Normal tissue function is also dependent on an adequate supply of oxygen through the 
blood vessels and unravelling the mechanisms that may be involved in disturbing or 
facilitating this maintenance of oxygen supply would offer therapeutic options to 
ameliorate or even cure a number of disorders such as cancer that are now leading 
causes of mortality.  Some of the main factors involved in this non-cancerous 
angiogenesis are certainly hypoxia and inflammation.  Hypoxia, via activation of 
hypoxia-inducible transcription factors (HIF), induces the expression of a number of pro-
angiogenic factors/stimuli such as VEGF, NO, PDGF and EphB4 (Vihanto et al., 2005).   Introduction 
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Figure 6.  Key players in the microvascular (tumour) environment.  A, Tumour cells produce 
proangiogenic factors such as VEGF, bFGF, angiopoietins, interleukin-8 and PlGF that result in   
endothelial cell migration and proliferation. B, Furthermore stromal cells such as fibroblastic, inflammatory 
and immune cells release angiogenic factor (e.g. chemokines such as SDF-1 and VEGF).  These factors 
as well as VEGF-A and PIGF may also recruit bone-marrow-derived angiogenic cells (BMC) and produce 
growth and survival factor for tumour cells such as EGFR ligands and hepatocyte growth factor (HGF).  c, 
PDGF-B that is produced by endothelial cells activates PDGFR-β resulting in  pericyte recruitment in the 
microvasculature.  From Ferrara and Kerbel, 2005.   
 
Although endothelial cells certainly initiate angiogenesis and are therefore essential for 
vascular development, it is the periendothelial structures that are crucial to complete 
vascular maturation by inhibiting endothelial cell proliferation and migration while 
producing the extracellular matrix in order to stabilize nascent vessels.  In this context 
another determinant that should certainly not be neglected is the influence of flow.  As a 
result of higher flow in the capillaries proximal to the aorta, coronary arteries become 
covered by smooth muscle cells earlier than veins (Vrancken Peeters et al., 1997).  In 
pathophysiological angiogenesis that is often induced by some degree of inflammation, 
monocytes/macrophages, platelets, mast cells and other leucocytes play a vital role as 
they are ‘attracted’ to sites of would healing or inflammation.  This is at least in part 
mediated by angiogenic factors such as bFGF, IGF-1, PDGF or VEGF (Pinedo et al., Introduction 
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1998) which then in turn produce angiogenic chemokines that attract amongst others 
endothelial cells and smooth muscle cells (Sunderkotter et al., 1994; Coussens and 
Werb, 2001).  
 
 
1.6  EETs, proliferation and angiogenesis 
 
Currently, relatively little is known about the molecular mechanisms underlying CYP 
epoxygenase/EET-induced proliferation and angiogenesis.  As mentioned above, one of 
the most detailed analyses of the mechanisms involved reported is the transactivation of 
the EGF receptor as a consequence of the matrix metalloproteinases-induced release 
of heparin-binding EGF-like growth factor (HB-EGF) from the extracellular membrane.  
The EET-mediated activation of the EGF receptor leads in turn to the activation of the 
kinase Akt and an enhanced expression of cyclin D1 (Figure 7).  All four EET-
regioisomers regulate endothelial cell proliferation by increasing Akt phosphorylation in 
endothelial cells, but for example in murine endothelial cells only the effects seen with 
5,6- and 14,15-EETs appear to be dependent on PI3K (Pozzi et al., 2005).  Recently it 
has been suggested that 11,12-EET can activate Akt/ PI3K by means of sphingosine 
kinase 1 (SK1) (Yan et al., 2008) in endothelial cells.  Other signalling pathways also 
contribute to the increase in cyclin D1 expression including the MAP kinase 
phosphatase-1 which decreases JNK activity (Potente et al., 2002).  Activation of Akt by 
EETs also induces the phosphorylation and therefore inhibition of the forkhead factors 
FoxO1 and FoxO3a and subsequently a decrease in the expression of the cyclin-
dependent kinase inhibitor p27
Kip1 (Potente et al., 2003).  
Furthermore, in human dermal microvascular endothelial cells 14,15-EET have been 
found to induce angiogenesis via Src-dependent increase in STAT-3-mediated VEGF 
expression (Cheranov et al., 2008). 
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Figure 7.  Angiogenic pathways activated by CYP2C-derived EETs in endothelial cells.  EETs are 
able to transactivate the EGF receptor via a mechanism that involves matrix metalloprotease (MMP)-
dependent heparin-binding EGF-like growth factor (HB-EGF) release.   EET-mediated activation of the 
EGF receptor results in Akt-activation and subsequent cyclin D1 expression.  Furthermore MAP kinase 
phosphatase-1 (MKP-1) activation which decreases JNK activity contributes to increased cyclinD1 
expression.  From Michaelis et al., 2003. 
 
 
1.7 Growth factors acting via endothelial cell-specific receptor 
tyrosine kinases  
 
The development of a functional vascular network requires a remarkable degree of 
coordination between different cell types undergoing complex changes and is 
dependent upon signals exchanged between these cell types.  A number of signal 
transduction systems and molecules, such as VEGF, are involved in these processes 
and during the subsequent maturation of the developing vasculature amongst others the 
PDGF-B/PDGF-β pathway is essential for the differentiation of mural cells into vascular 
smooth muscle cells or pericytes (Betsholtz et al., 2004).  Other lipid mediators have 
been implicated in this later maturation process and sphingosine-1-phosphate (S1P) 
has been reported to play a critical role in the recruitment of vascular smooth muscle Introduction 
 
  16
cells by endothelial cells as downregulation of one of its receptors results in defects in 
mural vessel coverage (Allende et al., 2003).   
The present study focused on two main factors that are known to be very important for 
the development of the vascular network: VEGF as one of the most potent inducers of 
vascular permeability and angiogenesis and EphB4 because of its high relevance for 
the guidance of vascular sprouts (Munarini et al., 2002). 
 
1.7.1 Vascular  endothelial  growth factor (VEGF) 
The VEGF family provided the first example of a growth factor specific for the 
endothelium.  During the early 1960s the human VEGF receptors were structurally 
characterized by cDNA cloning (Shibuya et al., 1990; Millauer et al., 1993).  The VEGF 
family currently consists of seven members (VEGF-A, VEGF-B, VEGF-C, VEGF-D, 
VEGF-E, VEGF-F and placental growth factor, PIGF), all of which have different 
physical and biological properties and act through specific tyrosine kinase receptors 
(VEGF-R1, VEGF-R2 and VEGF-R3).  Although these receptors are structurally highly 
related, they display interesting differences in their ability to respond to ligand binding 
with increased kinase activity and the spectrum of transduced biological responses 
ranges from the regulation of physiological to pathophysiological angiogenesis.   
VEGFR-2 has strong tyrosine kinase activity and transduces the major signals of 
angiogenesis via the phospholipase C protein kinase C pathway to activate MAP 
kinases and DNA synthesis.  One of the most important roles of VEGFR-2 is stimulation 
of endothelial cell survival and angiogenesis.  Its gene inactivation results, for example, 
in death at embryonic day 8.5 and 9 due to a failure in vasculogenesis (Shalaby et al., 
1995).  Furthermore, overactive VEGFR-2 signaling results in pathological angiogenesis 
including diabetic retinopathy and cancer.  VEGFR-1 plays a dual role, VEGFR-1 -/- 
mice die between embryonic day 8 and 9 (Fong et al., 1995), and this negative 
regulatory role is most likely due to trapping VEGF-A resulting in prevention of VEGFR-
2 activation by its ligand  (Hiratsuka et al., 1998).  However in the adult VEGFR-1 is a 
positive regulator (Shibuya and Claesson-Welsh, 2006) of vascular development.   
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1.7.2 EphB4 
The very large family of ephrins that act via endothelium-specific receptors known as 
Ephs have recently been identified and studied in vascular development and 
angiogenesis (Gale and Yancopoulos, 1999; Tallquist et al., 1999).  Eph receptors are a 
family of receptor tyrosine kinases that play a critical role in embryonic patterning, 
neuronal targeting, vascular development and adult neovascularisation.  Although first 
described due to their function in the nervous system, signalling via Eph receptors 
mediates critical steps of angiogenesis, including juxtacrine cell-cell contacts, cell 
adhesion to extracellular matrix, cell migration and proliferation.  
Ephs were first discovered in a human cDNA library screen for sequences homologous 
to the viral oncogene vfps (Hirai et al., 1987).  Unlike other families of RTK, which bind 
to soluble ligands, Eph receptors interact with cell surface-bound ephrin ligands which 
attach to the cell membrane either through a glycosylphosphatidyl inositol (GPI) anchor 
or a transmembrane domain. Based on how they attach to the cell membrane, Ephs 
have been divided in two subclasses, A and B, with EphB4 being the most prominent 
representative in vascular development.  Moreover these receptor-ligand interactions 
activate signalling pathways in a bi-directional fashion, through both the Eph receptors 
and ephrin ligands.  For example, mutant animals lacking EphB4 show a phenotype of 
disrupted vessel formation and early embryonic lethality (Gerety et al., 1999), but the 
exact role of EphB4 in angiogenesis is still largely unclear. Downstream signalling of 
Eph is very complex and involves amongst others activation of Abelson kinase and Src 
family kinases as well as Ras and Rho (Kullander and Klein, 2002). This is mirrored to 
some extent in the versatility that is involved when it comes to the Eph/ephrin system 
(Figure 8).  Depending on the exact setting as well as on spatial gradients in receptor 
and ligand distribution cell signalling ranges from adhesion to repulsion and makes 
prediction of certain scenarios challenging. Introduction 
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Figure 8.  Downstream Eph signalling.  Abelson (Abl) and Abl-related gene (Arg) bind the 
juxtamembrane region of EphB through a phosphorylation-independent interaction with EphB.  Activated 
Eph receptors suppress the extracellular-signal regulated kinase (ERK)/mitogen-activated protein kinase 
(MAPK) pathway.  Ephexin interacts with the Eph-receptor kinase domain and its activation affects a 
number of Rho GTPases-related processes.  GAP, GTPase-activating protein; PI3K, phosphatidylinositol 
3-kinase; FAK, focal adhesion kinase. LMW-PTP, low-molecular-weight protein tyrosine phosphatase; 
Nck, SH2–SH3 adaptor protein.  From Kullander and Klein, 2002.   
 
 
1.8  Aim of the study 
 
Our group has previously reported that CYP2C-derived EETs are involved in the 
regulation of endothelial cell homeostasis and angiogenesis.  The molecular 
mechanisms that account for the observed effects have only been partially elucidated 
and therefore the aim of this study was to further clarify the mechanisms involved in the 
angiogenic response mediated by CYP2C9-derived EETs in more physiologically-
relevant conditions than those addressed in previous studies. 
The first part of the study concentrates on the role played by EETs in EphB4 and VEGF 
signalling while the latter experiments were aimed at identifying new EET effector Introduction 
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pathways and the influence of the epoxides on cell-cell communication e.g. pericyte 
recruitment. 
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2.  Materials and Methods 
 
2.1 Materials 
 
All culture media, enzymes and buffer solutions as well as antibiotics for cell culture 
were from Invitrogen (Karlsruhe, Germany), cell culture plates and falcon tubes were 
from BD Biosciences (Heidelberg, Germany).  11,12-EET was purchased from Cayman 
Chemicals (Massy, France), growth factor reduced basement membrane matrix 
(Matrigel) was obtained from BD Biosciences (Heidelberg, Germany), thrombin was 
from Haemochrom Diagnostica GmbH (Essen, Germany).  Sulfaphenazole and all other 
substances were from Sigma (Deisenhofen, Germany). VEGF and bFGF were from 
PeproTech (Hamburg, Germany). 
14,15-Epoxyeicosa-5(Z)-enoic acid (14,15-EEZE) and MS-PPOH were synthesized as 
described (Gauthier et al., 2002) and provided by J.R. Falck (Department of 
Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, USA).  
Protein A Sepharose for the immunoprecipitation was from GE Healthcare (Freiburg, 
Germany) and Protein G Sepharose and dynabeads that were used for the isolation of 
murine lung endothelial cells were from Invitrogen (Karlsruhe, Germany). Materials and Methods 
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The following antibodies were used in the course of this study: 
Antibody Company  Method 
α-actin  Sigma, Deisenhofen, Germany  Matrigel 
immunohistochemistry 
β-actin  Sigma, Deisenhofen, Germany  Western blot 
Akt  Cell signaling, Danvers, MA, USA  Western blot 
Phospho-Akt  Cell signaling, Danvers, MA, USA  Western blot 
AMPK  New England Biolabs, Ipswich, MA, USA  Western blot 
Phospho-
Thr174AMPK 
New England Biolabs, Ipswich, MA, USA  Western blot 
CYP2C9  Acris, Hiddenhausen, Germany  Western blot 
EphB4   R&D Systems, Wiesbaden, Germany  In situ 
immunohistochemistry 
EphB4   Zymed, San Fransisco, USA  Western blot 
ephrinB2 R&D  Systems,  Wiesbaden, Germany  Western blot 
PECAM-1 (clone 
MEC 13.3) 
Santa Cruz Biotechnology, Heidelberg, 
Germany 
Immunohistochemistry 
PECAM-1  BD Bioscience, Wiesbaden, Germany  Matrigel 
immunohistochemistry 
Phosphotyrosine Santa  Cruz  Biotechnology, Heidelberg, 
Germany 
Immunoprecipitation 
 
 
2.2 Cell  culture 
 
Human endothelial cells were either isolated from human umbilical veins (HUVEC) of 
fresh umbilical cords as described (Busse and Lamontagne, 1991) or purchased from 
Promocell if used for transfection.  For the VEGF experiments HUVECs tested for the 
VEGF-signalling pathway were obtained from Cell Applications (San Diego, USA).   Materials and Methods 
 
  22
HUVECs were cultivated in MCDB 131 containing 8% fetal calf serum (FCS), L-
glutamine (10 mmol/L), basic fibroblast growth factor (bFGF, 1 ng/mL), epidermal 
growth factor (EGF, 0.1 ng/mL), ‘endothelial cell growth supplement’ with bovine brain-
derived heparin (ECGS/H, 0.4 %), penicillin (50 U/mL) and streptomycin (50 µg/mL). 
Porcine aortic endothelial cells (PAEC) were isolated by excising porcine aortas 
segments from freshly slaughtered pigs as described (Popp et al., 1996).  Under sterile 
conditions the aortas were cleaned of fat and connective tissue and sliced open 
longitudinally between the intercostal vessels.  Vessels were mounted between a plastic 
plate and a frame with the endothelial side facing upwards.  Endothelial cells were 
separated by incubating for 40 minutes at 37ºC with dispase followed by repeated 
pipetting.  Afterwards cells were diluted with M199 containing 0.1 % BSA, recovered by 
centrifugation (100g, 5 minutes) and resuspended in a 1:1 mixture of MCDB 131 and 
M199 (with 14% FCS, 6 mmol/L L-glutamine, 0.5 ng/mL bFGF, 0.05 ng/mL EGF, 0.2 % 
bovine brain-derived ECGS/H, 50 U/mL penicillin and 50µg/mL streptomycine) and 
seeded on culture dishes coated with fibronectin (BD Bioscience, Heidelberg, 
Germany). 
The murine lung microvascular endothelial cells were isolated
  from 3–4 month old 
animals as described (Fleming et al., 2005).  Briefly peripheral lung tissue was minced 
and digested for 1 h at 37°C
 in 0.1% collagenase-A (Boehringer Mannheim).  The digest 
was
 passed through a blunt 14-gauge needle and filtered through
 a 130 µm steel mesh.  
Cells were pelleted at 1200 rpm and
  resuspended in murine lung endothelial cell 
(MLEC) medium (37°C)
  containing 20% FCS, 35% DMEM, 35% F-12, 50 µg/mL 
endothelial
  mitogen (Biomedical Technologies, Stoughton, MA, USA), 2 mmol/L L-
glutamine, 100 µg/mL
 heparin, and 100 U/100 µg/mL penicillin-streptomycin.  To the 
suspended cells, magnetic beads (Dynabeads
® Sheep anti-rat IgG) were
 added and 
and incubated for 1 h at 4°C.  Cells
 were washed and selected in a magnetic field.
  
Cultures were grown to confluence and selected twice before
  being plated for 
experiments. 
First passage HUVECs were used throughout. Porcine aortic and murine lung 
endothelial cells were used up to passage five.  HUVECs prescreened for VEGF and 
HUVECs purchased from Promocell were used up to passage seven. 
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2.3  Transfection of endothelial cells 
 
HUVECs were transiently transfected using Gene Trans II (MobiTec, Göttingen, 
Germany), a lipophilic transfection reagent.  One day after they were seeded on 
fibronectin coated culture dishes (at approximately 80% confluence) cells were 
incubated for 4 hours with the GeneTrans-DNA complex in the smallest possible volume 
of MCDB with 0.1% BSA.  Afterwards, cells were left to recover in MCDB with 2% FCS, 
L-glutamine (10 mmol/L), bFGF (0.5 ng/mL), EGF (0.05 ng/mL), ECGS/H (0.2%), 
penicillin (50 U/mL) and streptomycin (50 µg/mL).  Transfection efficiency was 
approximately 30-40%. 
Murine lung endothelial cells were transfected accordingly using TransPass
TM HUVEC 
Transfection Reagent (New England BioLabs, Ipswich, MA, USA) and left to recover in 
DMEM/F12 with 2.5% FCS, 35% DMEM, 35% F-12, 50 µg/mL endothelial
 mitogen 
(Biomedical Technologies, Stoughton, MA, USA), 2 mmol/L L-glutamine, 100 µg/mL
 
heparin, and 100 U/100 µg/mL penicillin-streptomycin.   
 
 
2.4  Adenoviral infection of endothelial cells 
 
In some experiments endothelial cells were treated with adenoviral vectors to increase 
transgene expression.  The recombinant adenovirus expressing CYP2C9 sense was 
generated following transfection of the plasmid into human embryonic kidney cells (HEK 
293) according to the AdEasy system.  The CYP2C sense gene was incorporated into 
pAdTrack-CMV vector and the CYP2C antisense gene into pShuttle-CMV vector.  The 
AMPK viruses used were from K. Walsh (School of Nursing, Midwifery and Nutrition, 
James Cook University, Cairns QLD, Australia).  For the infection endothelial cells (80% 
confluent) were first serum-starved for 10 hours and then incubated with the 
recombinant adenovirus (10 pfU/cell) in MCDB 131 with 0.1% BSA for 4 hours.   
Afterwards, cells were left to recover in MCDB 131 with 2% FCS, L-glutamine (10 
mmol/L), bFGF (0.5 ng/mL), EGF (0.05 ng/mL), ECGS/H (0.2%), penicillin (50 U/mL) 
and streptomycin (50 µg/mL).  As described previously (Michaelis et al., 2005a) 
infection efficiency was between 90 and 100% and those cells infected with CYP2C9 
sense adenovirus generated approximately two-fold more 11,12- and 14,15-EET under Materials and Methods 
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basal conditions than cells infected with the control (CYP2C9 antisense) virus. This 
increase in EET production was sensitive to the CYP2C inhibitor miconazole. 
 
 
2.5  EET measurements by LC-MS/MS 
 
HUVECs were treated as described in the results section, harvested by scraping and 
the pellets (from approximately 8x10
6
 
cells) were suspended in 100 µL potassium 
phosphate buffer (0.1 mol/L, pH 7.2), hydrolyzed for 1 hour in NaOH (0.5 N) and 
neutralized with HCl (2 mol/L) before deuterated internal standards (5-HETE-d8, 12-
HETE-d8, 15-HETE-d8, 20-HETE-d6, 8,9-EET-d8, 11,12-EET-d8 and 14,15-EET-d8  
(Cayman, Massy, France)) were added.  A liquid-liquid-extraction was performed twice 
using ethyl acetate (0.5 mL).  After evaporation of the solvent in a vacuum block under a 
gentle stream of nitrogen, samples were reconstituted with 50 µL of methanol/water 
(1:1, v/v) and eicosanoids were determined with a Sciex API4000 mass spectrometer 
operating in the multiple reaction monitoring (MRM) mode.  Chromatographic separation 
was performed on a Gemini C18 column (150 x 2 mm I.D., 5 µm particle size, 
Phenomenex, Aschaffenburg, Germany). 
 
 
2.6  Transfection with antisense oligonucleotides  
 
In order to downregulate protein expression in HUVEC an antisense approach was 
used.  Endothelial cells were transiently transfected using Gene Trans II (MobiTec, 
Göttingen, Germany), a lipophilic transfection reagent.  One day after they were seeded 
on fibronectin coated culture dishes (at approximately 80% confluence) cells were 
incubated for 4 hours with the GeneTrans-DNA complex (DNA concentration: 2 µmol/L) 
in the smallest possible volume of MCDB with 0.1% BSA.  Afterwards cells were left to 
recover in MCDB with 2% FCS, L-glutamine (10 mmol/L), bFGF (0.5 ng/mL), EGF (0.05 
ng/mL), ECGS/H (0.2%), penicillin (50 U/mL) and streptomycin (50 µg/mL). 
Cells were treated with the following oligonucleotides (Biospring GmbH, Frankfurt am 
Main, Germany): 
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EphB4 antisense oligonucleotides:  5'-ATGGAGGCCTCGCTCAGAAA-3'   
EphB4 scrambled oligonucleotides:  5'-TACCTGAAGGTCAGGCGCAC-3'   
 
CYP2C  antisense:       5’-TCC  ATT GAA GCC TTC TCT TCT T-3’ 
CYP2C sense:         5’-AAG AAGAGA AGG CTT CAA TGG A-3’ 
 
The sequence of the CYP2C oligonucleotides spans the ATG and is 100% identical with 
human CYP2C8 and contains one mismatch to the other 3 human CYP2C isoforms.  
 
 
2.7  Downregulation by RNA interference  
 
In mouse lung endothelial cells RNA was downregulated by transfecting cells with one 
of three siRNAs directed against EphB4 using TransPass
TM HUVEC Transfection 
Reagent (New England Biolabs, Ipswich, MA, USA). 
 
EphB4siRNA1:       5’-AAG-UAG-GUC-AAG-UUC-GUG-3’ 
EphB4siRNA2:       5’-UGU-CUC-CUA-UGU-CAA-GAU-3’ 
EphB4siRNA3:       5’-AAU-CUU-GAC-AUA-GGA-GAC-3’ 
 
One day after they were seeded on fibronectin coated culture dishes (at approximately 
80% confluence) cells were incubated with the TransPass
TM HUVEC transfection 
reagent –DNA complex.  After 24 hours cells were left to recover in DMEM/F12 with 
2.5% FCS, L-glutamine (10 mmol/L), bFGF (0.5 ng/mL), EGF (0.05 ng/mL), ECGS/H 
(0.2%), penicillin (50 U/mL) and streptomycin (50 µg/mL). 
 
 
2.8  Reporter gene assay 
 
For maxi plasmid DNA preparation commercially available kits were used from Qiagen 
(Düsseldorf, Germany) and the DNA isolation was performed according to the 
manufacturer’s protocol.  Materials and Methods 
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PAECs were transiently co-transfected with the EphB4 promoter luciferase construct 
(amplified by PCR and cloned
 in KpnI and XhoI sites of the pGL3 enhancer luciferase 
vector
  (Promega, Mannheim, Germany)) as described above together with either 
pcDNA 3.1 or a plasmid encoding for CYP2C9.  After 36 hours, the cells were lysed in 
luciferase buffer (K2HPO4 and KH2PO4, pH 7.8, 0.5% TritonX-100, Dithiothreitol DTT 0.5 
mmol/L) on ice. Membrane fractions were separated by centrifugation (13000 rpm, 10 
minutes, 4ºC) and protein concentration in the lysate was determined photometrically at 
595 nm using Bradford solution; a solution of increasing BSA concentration was used 
as a reference for calibration.  Samples were equalised to a protein concentration of 1 
µg/µL, mixed with equal amounts of luciferase substrate and luciferase activity was 
measured according to the manufacturer’s protocol (Promega, Mannheim, Germany) in 
a luminometer.   
Endothelial cells expressing either VEGF-R1 or VEGF-R2 were transiently transfected 
with the non-coding 5’ region (-2088 to +21; kindly provided by Dr. P. Maurel, 
Montpellier, France) of CYP2C9 subcloned into pGL3basic (Promega, Mannheim, 
Germany).  After 12 hours, the cells were treated with either solvent (PBS, 140 mmol/L 
NaCl, 2.68 mmol/L KCl, 10 mmol/L Na2HPO4, 1.47 mmol/L KH2PO4; pH 7.0) or VEGF 
(30 ng/mL) for 6 hours. Thereafter, the cells were lysed in luciferase buffer and 
luciferase activity was assayed according to the manufacturer’s protocols (Promega, 
Mannheim, Germany).  Promoter activity was determined as luciferase activity relative 
to protein content. 
 
 
2.9 Protein  isolation 
 
Cells were washed with phosphate-buffered saline solution (PBS) and lysed on ice with 
a buffer containing 20 mmol/L TRIS-HCl, pH 7.5, 1% TritonX-100, 25 mmol/L β-
glycerolphosphate, 150 mmol/L NaCl, 10 mmol/L Na pyrophosphate, 20 mmol/L NaF, 
2mmol/L Na orthovanadat, 10 mmol/L okadaic acid and a protease inhibitor mix (2 
µg/ml antipain, 2 µg/mL aprotinin, 2 µg/mL chymostatin, 2 µg/mL leupeptin, 2 µg/mL 
pepstatin, 2 µg trypsinhibitor and 40 µg/mL phenylmethysulfonyllfluoride (PMSF)).   
Insoluble fractions were separated by centrifugation (13000 rpm, 10 minutes, 4ºC) and 
protein concentration in the lysate was determined. 
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2.10   Immunoprecipitation  
 
Cells were washed with PBS and lysed on ice in modified RIPA-buffer (150 mmol/L 
NaCl, 1 mmol/L EDTA, 1% Nonidet, 0.5% Na deoxycholate, 0.1% SDS, 20 mmol/L Tris, 
pH 8.0) containing a protease inhibitor mix (2 µg/mL antipain, 2 µg/mL aprotinin, 2 
µg/mL chymostatin, 2 µg/mL leupeptin, 2 µg/mL pepstatin, 2 µg trypsinhibitor and 40 
µg/mL PMSF and 1 mmol/L sodium orthovanadate) and the insoluble fractions were 
separated by centrifugation (13000 rpm, 10 minutes, 4ºC).  Afterwards protein lysates 
(30 µg) were incubated with 2 µL of a phosphotyrosine antibody (Santa Cruz 
Biotechnology, Heidelberg, Germany) for 90 minutes at 4ºC and then 30 µL of a mixture 
of Protein A and G Sepharose (GE Healthcare, München, Germany) was added.  After 
an additional 90 minutes immunoprecipitates were washed three times with RIPA buffer 
and were resuspended in sodium dodecylsulfate (SDS)-buffer.  The samples were 
separated by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS PAGE).   
 
 
2.11   Immunoblotting 
 
Following lysis, protein samples were separated by SDS-PAGE in a buffer solution 
consisting of 190 mmol/L glycine, 0, 1% SDS and 25 mmol/L TRIS-HCl.  The separated 
proteins were then transferred for 90 minutes at 250 mA (for 2 gels) in a buffer solution 
composed of 190 mmol/L glycine, 25 mmol/L TRIS-HCl and 20% methanol.  Afterwards 
the membranes were incubated in 3% BSA in TRIS buffered saline with 0,3% Tween-20 
(TBST, 50 mmol/L TRIS/HCl, 150 mmol/L NaCl) to block unspecific binding sites on the 
membrane.  After incubation with the according primary antibody diluted in 3% BSA 
overnight, multiple washing steps with TBST and another blocking step, membranes 
were incubated with a horseradish peroxidase conjugated secondary antibody diluted 
with TRIS buffered saline followed by repeated washing.  Membranes were subjected to 
a chemiluminescence reaction via the ‘Enhanced Chemiluminescence (ECL)’ system by 
mixing ECL-solution I (100 mM TRIS/Cl, pH 8.8, 2.5 mM luminol and 0.4 mM coumarin 
acid) and ECL-solution II (100 mM TRIS/Cl, pH 8.8 and 30% H2O2) and proteins 
detected by the first and secondary antibody were exposed to X-ray film in the 
darkroom. 
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2.12      RNA-Isolation and reverse transcriptase polymerase chain 
reaction (RT-PCR) 
 
Total RNA from cultivated endothelial cells was isolated as described (Chomczynski 
and Sacchi, 1987).  Endothelial cells were washed with PBS and lysed using phenol 
and guanidine isothiocyanate (Tri
®Reagenz, Sigma, Deisenhofen, Germany).   
Homogenized samples were incubated for 5 minutes at room temperature to permit the 
complete dissociation of the nucleoprotein complex.  Afterwards the solution containing 
RNA as well as DNA was mixed with 0.2 ml of chloroform per 1 ml of Tri
®Reagenz.   
Samples were shaken vigorously by hand for 15 seconds and incubated at room 
temperature for 2 to 3 minutes.  The two phases were separated by centrifugation for 30 
minutes at 12000g to dilute RNA in the upper, aqueous phase while the DNA stays in 
the lower organic phase.  RNA was transferred to a fresh tube and precipitated by 
adding isopropanol (100%).  Thereafter samples were incubated at room temperature 
for another ten minutes, centrifuged, washed with ethanol (75%) and diluted in water.  
RNA concentration was defined by photometric measurement at 260 nm. 
For the reverse transcriptase-polymerase chain reaction 1 µg RNA was used.   
Incubation with reaction buffer (Invitrogen, Karlsruhe, Germany), desoxynukleosid-5’-
triphophate (175 µmol/L of dATP, dCTP, dGTP and dTTP), dithiothreitol (1 mmol/L), 
oligo (dT) and reverse transcriptase (200 U, Invitrogen, Karlsruhe, Germany) for 60 
minutes at 37ºC resulted in cDNA-synthesis.  To avoid false positive results by 
contamination a negative control without reverse transcriptase was used.   
For the amplification of cDNA during the PCR (15 minutes at  95°C followed by 60 
cycles à 30 secondes at 95°C, 1 minute at 60 °C and 30 secondes at 72°C in a Mx4000 
multiplex quantitative PCR system (Stratagene, Heidelberg, Germany)) the following 
primers were used:  
18 S:      forward 5’ –CTTTGGTCGCTCGCTCCTC-3’ 
18 S:      reverse 5’- CTGACCGGGTTGGTTTTGAT-3’ 
 
CYP2C8:     forward: 5’-GGACTTTATCGATTGCTTCCTG-3’,  
reverse: 5’-CCATATCTCAGAGTGGTGCTTG-3’ Materials and Methods 
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To ensure equal amounts of cDNA were used, Pol2 RNA was amplified by qPCR 
(Assay on Demand, Applied Biosystems) and the amount of cDNA in the samples was 
calculated on the basis of the amplification of a serial dilution of a plasmid (CYP2C8) or 
the serial dilution of the cDNA (18S RNA). The CYP2C8 levels were normalized to that 
of Pol2. At least two RT reactions were performed using each RNA preparation and at 
least two PCR reactions were performed with each cDNA sample.  
 
 
2.13   In vitro angiogenesis assays 
 
2.13.1 Fibrin gel:  
To generate a fibringel, fibrinogen (1.5 mg/mL) was dissolved for 2 hours in MCDB 131 
supplemented with 0.1% BSA with penicillin (50 U/mL) and streptomycin (50 µg/mL), 
filtered through a sterile filter and portioned into a 24 well culture plate (250 µL per well).  
The gel was polymerized by the addition of thrombin (0.5 U/mL).  After 30 minutes at 
room temperature 1 ml MCDB 131 with 0.1% BSA was added to each well and the gels 
were equilibrated in a cell incubator at 37ºC overnight.  Thereafter, HUVEC in MCDB 
with 4% FCS, L-glutamine (10 mmol/L), bFGF (0.5 ng/mL), EGF (0.05 ng/mL), ECGS/H 
(0.2%), penicillin (50 U/mL) and streptomycin (50 µg/mL) were seeded onto the gel and 
stimulated.  After 24 hours angiogenesis was quantified in three randomly chosen fields 
of view by measuring tube length with a computer-assisted microscope. 
 
2.13.2 Spheroid assay:  
For the three dimensional spheroid assay spheroids containing 400 cells were 
generated by the hanging drop method.  Therefore, 25 µl of cell suspension (containing 
400 cells) in endothelial growth medium (EGM, Clonetics (Cambrex Bio Science, 
Wakersville, Inc. USA)) containing 10% FCS, human epidermal growth factor (hEGF), 
bovine brain extract (BBE), penicillin (50 U/mL) and streptomycin (50 µg/mL) and 20% 
carboxymethyl cellulose (Sigma, Deisenhofen, Germany) was dispensed on cell culture 
plates to form individual drops, inverted and incubated at 37ºC overnight.  After 24 
hours, trays were uprighted and the drops containing spheroids of a defined cell number 
were harvested by flushing the tray with 5 mL of PBS containing 10% FCS.  A collagen Materials and Methods 
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stock solution was prepared prior to use by mixing 8 vol. of acidic collagen extract of rat 
tails (Collagen Type I, Rat Tail, BD Biosciences, Heidelberg, Germany, equilibrated to 2 
mg/mL) with Medium 199 (Sigma, Deisenhofen, Germany), HEPES (Invitrogen; 1 vol.) 
and 0.1 N NaOH (approx.  1 vol.) to adjust the pH to 7.4.  This stock solution (0.5 ml) 
was mixed with 0.5 ml room temperature endothelial basal medium (EBM, Clonetics, 
Cambrex Bio Science, Wakersville, Inc. USA)) containing 40% FCS and 0.5% (w/v) 
carboxymethylcellulose to prevent sedimentation of spheroids prior to polymerization of 
the collagen gel and 50 spheroids.  The spheroid-containing gel was rapidly transferred 
into prewarmed (37ºC) 24 well plates and allowed to polymerize (30 minutes).   
Thereafter, 250 µl EGM containing 2% FCS and stimulants were pipetted on top of the 
gel and were incubated at 37°C in 5% CO2 at 100% humidity.  After 24 hours, 
angiogenesis was quantified by measuring the cumulative length of all of the capillary 
like sprouts originating from the central plain of an individual spheroid using a computer-
assisted microscope.  At least 5 spheroids per experimental group and experiment were 
analyzed.  This analysis takes into consideration that the angiogenic response induced 
by a specific substance is more appropriately reflected by the length of individual 
capillary-like sprouts as well as the number of capillary like sprouts.  
 
 
2.14   In vivo angiogenesis assays 
 
Female C57BL/6 mice
 (8 weeks old) were lightly anesthetized with chloralhydrate (200 
µL of a 4% solution, s.c.).  When mice were asleep hair on the back was removed with 
an electric razor to allow a better visibility during the implantation of the Matrigel.   
Afterwards, 0.5 mL of Matrigels were impregnated with heparin (0.0025 units/mL s.c.), 
11,12-EET (10 µmol/L) containing either a control siRNA (GFP; 2 µmol/L) or siRNA 
directed against EphB4 (siRNA1; 2 µmol/L), VEGF (150 ng/mL), EEZE (100 µmol/L) or 
a combinations of VEGF and EEZE and were injected along
 the dorsal midline on each 
side of the spine.  When the gel solidified, mice were transferred to their cage and put 
on a heated blanket to avoid hypothermia.  After seven days the mice were sacrificed, 
the Matrigel plugs removed, embedded in Tissue Tek and frozen at -20ºC.  Plugs were 
then either cryo-sectioned (10 µm) and processed for staining for PECAM-1 (BD 
Biosciences, Heidelberg, Germany), α-actin (Sigma, Deisenhofen, Germany) and 
isolectin (Sigma, Deisenhofen, Germany) as described above or harvested and washed Materials and Methods 
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with PBS.  The latter samples were mixed with water (200 µL) on ice, homogenized with 
an electric mixer and centrifuged at 14000 rpm for 15 minutes to remove particulate 
material.  Afterwards 100 µL of Matrigel lysate and 300 µL Drabkins solution (Sigma, 
Deisenhofen, Germany) were mixed and incubated for 15 minutes at room temperature.  
Drabkins solutions alone served as the blank value and the concentration of the 
hemoglobin contained in the plugs was determined at 595 nm by analysing 1 µl of 
sample in a spectrophotometer (NanoDrop Technologies, Fisher Scientific GmbH, 
Schwerte, Germany); murine haemoglobin was used for calibration.  In some 
experiments Matrigel implants were fixed in zinc fixative (0.1M TRIS-buffer, calcium-
acetate, zinc acetate and zinc chloride) overnight, dehydrated using alcohol and 
isopropanol and processed for paraffin sectioning as described in the 
immunohistochemistry section.  EphB4 expression in the Matrigel plugs was determined 
using a polyclonal goat anti-mouse EphB4 antibody in combination with an enhanced 
detection method (Envision™, DAKO), DAB and Mayers Hematoxylin Solution (Sigma, 
Deisenhofen, Germany).  
In order to demonstrate perfusion in the Matrigel plug isolectin was injected through the 
tail vein 30 minutes before animals were sacrificed. 
Vessel formation was quantified manually as well as using a computer-assisted 
program (Nikon NIS-Elements) analyzing at least five sections per plug. Infiltration of 
endothelial cells (vessel formation index) and smooth muscle cells (stabilised vessel 
formation index) were scored blindly by four non-biased observers according to a 
predetermined scoring system. The scores were as follows: 0 no effect, 1 isolated 
endothelial cells, 2 clusters of endothelial cells but no distinct tube formation, 3 
endothelial tube formation with little or no coating by α-actin positive cells and 4 
complete coating of endothelial cells with α-actin positive cells. To facilitate comparison 
between the different groups the scores were normalized with respect to the effects 
observed in the control group.   
Mesenteric arteries were isolated from male adult NMRI mice and incubated for 18 
hours in DMEM supplemented with 15% FCS and either solvent (0.1% DMSO) or 
11,12-EET (10 µmol/L). Blood vessels were then fixed in zinc overnight, dehydrated 
using alcohol and isopropanol as described above and processed for paraffin 
sectioning.  Staining for EphB4 was performed using paraffin sections (4 µm) and the 
polyclonal anti-mouse EphB4 in combination with Envision™ and tyramide-Cy3 (Perkin 
Elmer, Rodgau, Germany) according to the manufacturer's instructions.  EphB4 staining Materials and Methods 
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intensity was determined by using the Cell^R software analysing at least two different 
sections per experimental group and animal.  Exposure times during digital imaging 
were kept constant.  
 
 
2.15   Immunohistochemistry 
 
For immunohistochemistry Matrigel Plugs were removed and either imbedded in Tissue 
Tek (Sakura Finetec, Torrance, USA) and frozen at -80ºC or fixed in zinc fixative 
overnight and embedded in paraffin.   
Tissue Tek embedded samples were cryo-sectioned (10 µm) and put on glass 
coverslips.  Afterwards sections were fixed with 4% paraformaldehyde in PBS, washed 
with PBS and 0.2% glycine, treated with blocking buffer (10% horse serum in TBST) 
and incubated with the primary antibody (diluted in PBS 1:100 to 1:500) overnight.  On 
the next day, sections were washed with PBS to remove excessive primary antibody 
and incubated with the FITC- or Cy3-coupled secondary antibody (Jackson 
ImmunoResearch Laboratories, West Grove, PA, USA).  Thereafter, sections were 
repeatedly washed with PBS and finally with deionised water and imbedded with 
fluorescence mounting medium (DAKO, Carpinteria, CA, USA).  Sections were 
analysed with a confocal microscope at a wavelength of 633, 564 and 488 nm. 
Paraffin embedded sections were dehydrated in a series of xylol, isopropanol, 99-96% 
ethanol, 85% ethanol, 70% ethanol and destillated water for 5 minutes each.  They were 
first rinsed in 3% H2O2 for 10 minutes and afterwards in H2O and treated with blocking 
buffer (0.25% casein, 15 mmol/L sodium azide and 0.1% bovine serum albumin in 50 
mmol/L TRIS-HCl pH 7.6) for 30 minutes.  Afterwards sections were incubated with goat 
anti-mouse EphB4 (1:200) (R&D Systems, Wiesbaden, Germany) in blocking buffer at 
4ºC overnight.  The next day sections were repeatedly washed in TBST, incubated with 
secondary antibody diluted (1:100) in blocking solution for 1 hour, washed with TBST 
and incubated with DAKO-Envision™ (DAKO, Carpinteria, CA, USA) enhanced 
detection method in combination with EphB4 antibody for 30 minutes at room 
temperature.  After washing with TBST to remove excess fluid, sections were developed 
with 3, 3’-diaminobenzidine enhanced liquid substrate system solution A and B (DAB), 
Sigma) for 1-5 minutes.  After the development process was stopped with H2O, sections Materials and Methods 
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were incubated with Mayers Hematoxylin Solution (Sigma, Deisenhofen, Germany) for 
30 seconds and rinsed for 5-10 minutes under running tap water.  After a series of wash 
steps with H2O, 70% ethanol, 85% ethanol, 99-96% ethanol, isopropanol, xylol for 5 
minutes each, sections were embedded in DePex mounting medium (Sigma, 
Deisenhofen, Germany). 
 
 
2.16  Contrast enhanced sonography  
 
For in vivo imaging with contrast enhanced sonography mice were anaesthetized with 
oxygen and isoflurane (3%).  Ultrasonography was performed when at 14 MHz at low 
mechanical index in a pulse inversion mode on a clinical ultrasound scanner (Sequoia, 
Siemens/ Acuson, USA).  After i.v. injection of 100 µl contrast media (Sono Vue, 
Bracco, Germany) the change of signal intensity (in dB) in the respective Matrigel plugs 
was recorded over time.  Relative peak enhancement of the signal-intensity-time curves 
in the left and right Matrigel plugs of the same animal was determined with an integrated 
software tool of the scanner. 
 
 
2.17   Statistical analysis 
 
Data are expressed as mean ± s.e.m (standard error of mean). Statistical analysis of 
Matrigel plugs analyzed by ultrasound was performed using a paired t test.  For all other 
statistical comparisons evaluation
 was performed with Student’s t test for unpaired data 
or one-way ANOVA followed by a Bonferroni t test. Values of P<0.05 were considered
 
statistically significant. Results 
 
  34
3. Results 
 
3.1  Effect of CYP2C9 on EphB4 expression  
 
Although CYP2C protein is expressed in native endothelial cells, mRNA as well as 
protein expression levels decrease rapidly following cell isolation (Fisslthaler et al., 
1999).  Already after the second passage protein levels can no longer be detected 
(Vernia et al., 2001).  Consequently in order to analyse effects and the biological 
function of CYP2C-derived EETs in vitro the protein needs to be upregulated either by 
pharmacological stimuli or hemodynamic stimuli (e.g. shear stress), by hypoxia as 
described (Michaelis et al., 2005a) or by using adenoviral constructs to overexpress 
CYP2C.   
To determine whether or not a link exists between CYP2C9 and the expression of the 
tyrosine kinase EphB4, HUVECs were infected with either a control (CYP2C9 
antisense) adenovirus or CYP2C9 encoding virus.  While low levels of EphB4 were 
detected in the endothelial cells employed, CYP2C9-overexpression resulted in a 4-fold 
increase in EphB4 expression within 24 hours compared to control virus-treated cells 
(Figure 9A).  There was no effect on CYP2C9 expression in solvent treated cells (data 
not shown).  The increase in EphB4 expression could be attributed to elevated CYP 
epoxygenase activity as the CYP2C9-induced increase in EphB4 expression was 
inhibited in the presence of the epoxygenase inhibitor, MSPPOH (10 µmol/L; Figure 
9B). 
Binding of the receptor EphB4 to its ligand ephrinB2 and subsequent signalling results 
in its phosphorylation.  In order to address whether or not increased CYP2C levels also 
results in increased in EphB4 phosphorylation, HUVECs were treated with either control 
or the CYP2C9 virus and a immunoprecipitation of tyrosine phosphorylated receptor 
proteins was performed (Figure 10).  CYP2C9 overexpression resulted in tyrosine 
phosphorylation of EphB4 as assessed by Western blotting using an antibody directed 
against EphB4. 
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Figure 9.  Effect of CYP2C9 overexpression on EphB4 expression in vitro.  HUVECs were infected 
with either a control (CTL) adenovirus or CYP2C9 encoding virus for overexpression (CYP2C9).   
Experiments were performed in the absence (A) and presence (B) of MSPPOH (MS) (10µmol/L).  The bar 
graphs summarize data obtained in 3-9 independent experiments; *P<0.05, **P<0.001 versus the 
respective CTL/Sol. 
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Figure 10.  Effect of CYP2C9 overexpression on the tyrosine phosphorylation of EphB4 in HUVEC. 
Cells were treated with either control (CTL) or CYP2C9 adenoviruses 48 hours before harvesting and the 
immunoprecipitation (IP) of tyrosine phosphorylated (p-Tyr) proteins.  The tyrosine phosphorylation of 
EphB4 as well as EphB4 expression in the lysate pre-IP was then assessed by Western blotting using an 
antibody directed against EphB4.  Similar results were obtained in 2 additional experiments. 
 
The activation of CYP epoxygenases not only results in the generation of EETs, but 
also in a series of other biologically active metabolites, e.g. HETEs as well as in 
production of reactive oxygen species.  To ensure that the increase in EphB4 
expression can be attributed to elevated EET levels the effect of exogenously applied 
11,12-EET on EphB4 expression was assessed.  Exogenously applied 11,12-EETs also Results 
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elicited a time- (Figure 11A), and concentration-dependent increase in endothelial 
EphB4 expression (Figure 11B). 
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Figure 11.  11,12-EET-induced increase in EphB4 expression.  Stimulation of HUVECs with 11,12-
EET (1µmol/L) results in a time- and concentration-dependent increase in EphB4 expression.  EphB4 
expression was assessed after 4, 8, 24 and 48 hours (A) and at 24 hours for the dose response curve at 
0.1, 0.3, 1 and 3 µmol/L (B).  The bar graphs summarize data obtained in 3-9 independent experiments; 
*P<0.05, **P<0.001 versus the respective CTL/Sol.   
 
EphrinB2 is the main ligand for EphB4 but is also capable of acting as a signal-
transducing
 molecule itself, a process referred to as "reverse signaling”.  Traditionally, 
the ligand has been reported to promote adhesion, migration, chemotaxis, capillary 
network formation, and sprouting angiogenesis (Füller et al., 2003; Hamada et al., 
2003).  To clarify whether there is also a link between CYP2C9 and ephrinB2 
expression that could account for the increase in EphB4 activation, murine lung 
endothelial cells were infected with control or CYP2C9.  EphrinB2 was expressed by the 
endothelial cells used, but there was no detectable change in the expression of the 
protein following the overexpression of CYP2C9 (Figure 12). 
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Figure 12.  Effect of CYP2C9 overexpression on ephrinB2 expression in vitro.  Murine lung 
endothelial cells were treated with solvent (Sol), control virus (CTL) or a CYP2C9 overexpressing virus 
(CYP) for 6, 24 and 48 hours and ephrinB2 expression levels were assessed by Western blot analysis.  
Similar results were obtained in 2 additional experiments. 
 
 
3.2  Role of CYP2C9-induced EphB4 expression in angiogenesis in 
vitro 
 
The results of the in vitro experiments showed clearly an involvement of CYP2C in the 
EphB4 mediated signalling cascade.  However, the exact role of EphB4 was unclear. 
As mentioned earlier crucial steps during angiogenesis are proliferation and 
differentiation of endothelial cells to form vascular tubes.  Endothelial cell migration and 
the degradation of the extracellular matrix are essential steps in this angiogenic 
process.  Prior to migration endothelial cells have to degrade the surrounding matrix 
which consists mainly of collagens, elastin, fibronectin and proteoglycans.  These 
processes can be investigated in vitro in two-or three dimensional angiogenesis assays 
that are based on growth matrices similar to the in vivo situation (i.e. collagen, fibrin and 
Matrigel).  To assess the impact of EphB4 on CYP2C9-mediated angiogenesis in vitro, 
a modified Matrigel sprouting assay was used.  In an initial step we established an 
antisense oligonucleotide protocol to down regulate EphB4 levels in the endothelial cells 
studied.  To this end endothelial cells were treated with scrambled or antisense 
oligonucleotides directed against EphB4.  While the scrambled oligonucleotides were 
without effect, the EphB4 antisense oligonucleotides decreased basal EphB4 protein 
levels in HUVEC and completely prevented the CYP2C9-induced increase in protein 
expression (Figure 13A).  
Next endothelial cells were incubated with EphB4 antisense oligonucleotides before 
generating spheroids and sprouting was assessed in the collagen based three-
dimensional angiogenesis assay.  A significantly attenuated CYP2C9-induced (24 Results 
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hours) sprout formation was observed in the presence of the EphB4 antisense 
oligonucleotides (Figure 13B) compared to control cells treated with scrambled 
oligonucleotides.  
 
CTL 2C9 CTL 2C9
0
100
200
300
T
u
b
e
 
l
e
n
g
t
h
 
(
%
 
C
T
L
)
EphB4
β-actin
A
CTL 2C9 CTL 2C9
0
100
200
300
400
E
p
h
B
4
/
β
-
a
c
t
i
n
 
(
%
 
C
T
L
)
EphB4 Scr EphB4 As EphB4 Scr EphB4 As
***
CTL 2C9
As Scr
2C9 + As
CTL + Scr CTL + As
2C9 + Scr
2C9 CTL
**
B
CTL 2C9 CTL 2C9
0
100
200
300
T
u
b
e
 
l
e
n
g
t
h
 
(
%
 
C
T
L
)
EphB4
β-actin
A
CTL 2C9 CTL 2C9
0
100
200
300
400
E
p
h
B
4
/
β
-
a
c
t
i
n
 
(
%
 
C
T
L
)
EphB4 Scr EphB4 As EphB4 Scr EphB4 As EphB4 Scr EphB4 As
***
CTL 2C9
As Scr
2C9 + As 2C9 + As
CTL + Scr CTL + Scr CTL + As CTL + As
2C9 + Scr 2C9 + Scr
2C9 CTL
**
B
 
 
Figure 13.  Effect of EphB4 antisense oligonucleotides in CYP2C9 overexpressing cells.  (A) 
HUVECs were first infected with either a control (CTL) adenovirus or CYP2C9 encoding virus for 
overexpression (CYP2C9) and then transfected with EphB4 antisense oligonucleotides (As) or control 
(scrambled) oligonucleotides (Scr).  (B) Endothelial cell sprouting was assessed in a collagen based 
spheroid assay.  HUVECs were infected with either control (CTL) or CYP2C9 adenoviruses and 
transfected with EphB4 antisense (As) or scrambled (Scr) oligonucleotides.  After 24 hours, spheroids 
were formed and seeded into a collagen gel after an additional 24 hours.  Sprouting was assessed after 
48 hours in the gel.  The bar graphs summarize data obtained in 3-10 independent experiments; 
**P<0.01, ***P<0.001 versus CTL. 
 
 
3.3  Role of the PI3K signalling pathway in CYP2C-induced 
angiogenesis 
 
So far relatively little is known about the signalling pathways upstream of EphB4 and 
most of the proteins identified in the Eph receptor downstream signalling pathways have Results 
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been implicated in regulating cell morphology, attachment and motility (Cheng et al., 
2002).  The PI3K can be activated by a variety of extracellular signals and is involved in 
a number of cellular processes including cell proliferation, survival, protein synthesis, 
and tumour growth.  As CYP2C-derived EETs, in particular 11,12- and 14,15-EET, have 
been reported to activate the PI3K/Akt signaling pathway in endothelial cells (Fleming et 
al., 2001a), the effects of CYP2C9 overexpression and the consequences of PI3K 
inhibition on this response were assessed. 
Initially the effect of overexpression of CYP2C9 on EphB4 promoter activity was 
characterized.  CYP2C9 increased EphB4 promoter activity compared to that detected 
in cells transfected with pcDNA (Figure 14A).  To study whether or not this increase in 
EphB4 promoter activity was mediated by PI3K the effect of the PI3K inhibitors 
LY294002 (1.5 µmol/L) and wortmannin (100 nmol/L)  on this increase in luciferase 
activity was investigated.  Treatment with both inhibitors resulted in similar inhibitory 
effects on EphB4 promoter activity (Figure 14A) as well as at protein level (Figure 14B).  
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Figure 14.  Effect of PI3K/Akt pathway inhibition on EphB4 promoter activity and protein 
expression in cells lacking or overexpressing CYP2C9.  (A) Endothelial cells were either transfected 
with CYP2C9 or a control plasmid (cDNA) and the EphB4 promoter and promoter activity was assessed 
in the absence and presence of LY294002 (LY) (1.5 µmol/L).  (B) HUVECs were infected with either a 
control (CTL) adenovirus or CYP2C9 encoding virus for overexpression (CYP2C9) was assessed in the 
absence and presence of LY294002 (LY) (1.5 µmol/L) and wortmannin (W) (100 nmol/L).  The bar graphs 
summarize data obtained in 3-6 independent experiments; *P<0.05, **P<0.01, ***P<0.001 versus the 
respective CTL.  
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Wortmannin and LY294002 are not completely specific for the PI3K (Knight and Shokat, 
2007).  Therefore we confirmed that CYP2C9 overexpression increased Akt 
phosphorylation (Figure 15A) and determined whether or not a dominant negative Akt 
mutant could inhibit the CYP2C9-induced increase in EphB4 expression. As before, 
EphB4 expression increased in cells treated with CYP2C9 adenoviruses.  However, no 
increase in EphB4 was observed in cells overexpressing CYP2C9 and transfected with 
the dominant negative Akt mutant (Figure 15B). 
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Figure 15.  Effect of CYP2C9 on Akt phosphorylation and effect of a dominant DN Akt on the 
CYP2C9-induced expression of EphB4.  HUVECs were infected with either a control (CTL) adenovirus 
or CYP2C9 encoding virus for overexpression (CYP2C9) and transfected with a DN Akt.  Akt 
phosphorylation in CYP2C9-overexpressing cells (A) as well as the effect of DN Akt on EphB4 expression 
in CYP2C9 overexpressing cells was analysed (B) by Western blot.  The bar graphs summarize data 
obtained in 3-4 independent experiments; *P<0.05, **P<0.01, ***P<0.001 versus the respective CTL.  
 
 
3.4  Role of EETs in cell proliferation and angiogenesis in situ 
 
The results of the studies detailed above clearly describe a correlation between CYP2C-
derived EETs and EphB4 expression in vitro.  It should be noted that ephrinB2 is 
classified as an arterial marker whereas EphB4 expression was thought to be restricted 
to venous endothelial cells (Gerety et al., 1999; Shin et al., 2001).  In this study EphB4 
expression was confirmed in venous endothelial cells, but to further characterize the 
(patho)physiological relevance of such effects and eventually be able to transfer these Results 
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observations to the in vivo situation, EET-mediated EphB4 expression was further 
characterized in situ. 
Isolated mesenteric arteries and veins were incubated with either solvent (DME medium 
containing 15% FCS) or 11,12-EET (1 µmol/L) and EphB4 was assessed by 
immunofluorescence after 18 hours. Quantification of fluorescence staining confirmed 
the EET-induced increase in EphB4 levels in mesenteric arteries (Figure 16A). Although 
EphB4 is reported to be preferentially expressed in veins (Wang et al., 1998) a much 
weaker response was detected in mesenteric veins treated with 11,12-EET (Figure 
16B). 
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Figure 16.  Effect of 11,12-EET on EphB4 expression in situ.  Mesenteric arteries (A) and veins (B) 
were incubated with solvent (Sol) or 11,12-EET and the expression of EphB4 (red) and PECAM-1 (green) 
was assessed.  The bar graph summarizes data obtained using vessels from 3 different animals; *P<0.05 
versus Sol.  
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3.5  Role of CYP-induced EphB4 expression in vivo 
 
The in vitro angiogenesis assay revealed a link between EphB4 and CYP2C-derived 
EETs, but even though an increase in EphB4 expression after EET-stimulation could 
also been confirmed in situ the ultimate physiological relevance needs to be assessed 
in vivo.  Therefore the next crucial step was to evaluate and further specify the effects 
seen in vitro in an in vivo angiogenesis assay. 
To perform studies targeting EphB4 expression in endothelial cells invading Matrigels 
implanted into mice it was initially necessary to develop an siRNA approach that 
downregulated murine EphB4 levels.  Therefore, murine lung endothelial cells were 
treated with three different siRNAs directed against EphB4 and EphB4 levels assessed 
under control conditions and following CYP2C9 overexpression.  The overexpression of 
CYP2C9 in murine lung endothelial cells increased the expression of EphB4 as 
detected in HUVECs.  Two of the siRNA tested (siRNA1 and siRNA2) prevented the 
CYP2C9-induced increase in EphB4 expression but only one of them (siRNA1) also 
decreased basal levels of the protein (Figure 17). 
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Figure 17.  SiRNA-mediated downregulation of EphB4 in murine endothelial cells.  Mouse lung 
endothelial cells were infected with either control (CTL) or CYP2C9 (2C9) adenoviruses and transfected 
with three different siRNAs directed against EphB4. The bar graph summarizes data obtained in 3 
independent experiments; *P<0.05 versus CTL.  
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Having identified an effective siRNA, the next step was to impregnate Matrigels with 
solvent or 11,12-EET in the absence and presence of either a control siRNA (GFP) or 
the siRNA1 against EphB4.   These Matrigels were then implanted in 8 week old female 
C57/BL6 mice (two per animal, one on each side of the spine) for a total of 7 days.  
Thereafter, the infiltration of endothelial and smooth muscle cells into the Matrigel plugs 
was assessed by immunohistochemistry.  While PECAM-1 positive endothelial cells 
could be detected in plugs treated with solvent, fully formed vessels (i.e. PECAM-1 
positive tube-like structures covered by α-actin positive cells) were detected in plugs 
impregnated with 11,12-EET (Figure 18A).   
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Figure 18.  Effect of downregulating EphB4 on angiogenesis in vivo.  Matrigel was impregnated with 
solvent (Sol) or 11,12-EET (10 µmol/L) together with either a control siRNA or EphB4 (siRNA1) and 
injected subcutaneously dorsally in mice.  After 14 days (A) cryosections of the Matrigel plugs were 
stained for PECAM-1 (red) and α-actin (green) cells.  (B) General appearance and hemoglobin (Hb) 
content of 11,12-EET-impregnated Matrigel plugs also containing either the CTL or EphB4 siRNA. The 
bar graphs summarize data from 3-4 animals per group; *P<0.05, **P<0.01 versus CTL siRNA-containing 
plugs.  
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These plugs were also blood perfused as they not only had a reddish colour suggesting 
that vessels invaded the plug, but also contained measurable levels of haemoglobin 
(Figure 18B).  The inclusion of EphB4 siRNA1 in the Matrigel plugs completely 
prevented 11,12-EET-mediated infiltration of endothelial and smooth muscle cells into 
the plug and the accumulation of haemoglobin. 
Apart from demonstrating how crucial EphB4 is to the EET-mediated angiogenic 
response these data highlight that the impregnation of Matrigel with 11,12-EET results 
in recruitment of endothelial cells as well as smooth muscle cells to generate functional 
vessels.  It is however not known if EETs also have an effect on the recruitment of 
pericytes, the vascular mural cells embedded within the vascular basement membrane 
of blood microvessels, where they make specific focal contacts with the endothelium.  
Staining for desmin, a specific pericyte marker, also revealed a role of EETs in the 
recruitment of pericytes (Figure 19).  This EET-mediated increased infiltration of 
desmin-positive structures was abolished by siRNA directed against EphB4, whereas 
control siRNA had no effect. 
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Figure 19.  Effect of CYP2C9-derived EETs on EphB4-induced pericyte recruitment.  Representative 
pictures showing desmin (green) and PECAM-1 (red) expressing cells in the Matrigel plug after treatment 
with solvent (Sol) or 11, 12-EET and with or without siRNA directed against murine EphB4. 
 
The results of the staining for PECAM-1, smooth muscle cells and pericytes clearly 
suggests that EphB4 is involved in the EET-mediated angiogenic response, but at this 
stage this does not provide any evidence that EphB4 is present in vessels formed after 
stimulation with EET.  Hence EET-impregnated Matrigel plugs were stained for EphB4.  
Compared to control plugs that were treated with solvent the vessel like structures that 
formed within those plugs expressed EphB4 (Figure 20). 
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Figure 20.  Effect of 11,12-EET on EphB4 expression in the Matrigel Plug.  Representative section 
showing EphB4 expression in a Matrigel plug impregnated with 11,12-EET (10 µmol/L) 7 days after 
subcutaneous injection in mice.  Similar pictures were taken from plugs of three additional mice. 
 
 
3.6  Effect of VEGF on CYP2C expression 
 
VEGF is a key regulator of physiological and pathological angiogenesis.  In vitro, VEGF 
induces endothelial cell proliferation, migration as well as being an endothelial cell 
survival factor.  Since the expression of VEGF is dependent on hypoxia (Levy et al., 
1996) and it has recently been shown that CYP2C8 is implicated in hypoxia-induced 
angiogenesis (Michaelis et al., 2005b) we postulated a link between VEGF- and CYP 
epoxygenase signalling. 
Stimulation of endothelial cells with VEGF increased CYP2C mRNA (Figure 21A) and 
protein levels (Figure 21B) in primary cultures of human endothelial cells.   
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Figure 21.  Effect of VEGF on the expression and activity of CYP2C in endothelial cells.  Time 
course showing the effect of VEGF (30 ng/mL, 3 to 48 hours) on the expression of (A) CYP2C mRNA and 
(B) CYP2C protein in HUVECs The bar graphs summarize data obtained in 7-13 independent 
experiments; *P<0.05, **P<0.01, ***P<0.001 versus control (CTL). 
 
VEGF also regulates CYP2C9 at the transcriptional level as stimulation with VEGF 
increased CYP2C9 promoter activity in cells expressing VEFR-1 or VEGFR-2 (Figure 
22).   
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Figure 22.  Effect of VEGF on the CYP2C9 promoter activity.  Porcine endothelial cells 
overexpressing VEGF-R1 or VEGF-R2 were transfected with the CYP2C promoter construct 14 hours 
prior to stimulation with VEGF (30 ng/mL, 6 hours).  The bar graphs summarize data obtained in 7-13 
independent experiments; *P<0.05, **P<0.01, ***P<0.001 versus control (CTL). 
 Results 
 
  47
The CYP2C9 promoter was used, because we were unable to generate a CYP2C8 
promoter construct, which seems to be the more relevant CYP in endothelial cells.   
Consequently we had to rely on data from the homologus 2C9 enzyme. 
To confirm that as a direct consequence of the increase in CYP epoxygenase 
expression after VEGF stimulation 11,12-EET levels would increase, endothelial cells 
were stimulated with VEGF and 11,12-EET levels were measured by LC/MSMS.  VEGF 
resulted in elevated EET levels, an effect that was sensitive to the CYP epoxygenase 
inhibitor, miconazole (Figure 23).   
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Figure 23.  Effect of VEGF on 11,12-EET production in HUVECs.  Cells were stimulated with VEGF 
(30 ng/ml), in some experiments in the presence of miconazole (Mic, 3 µmol/L) and after 24 hours 11,12-
EET levels were measured by LC-MS/MS.  The bar graphs summarize data obtained in 3-10 independent 
experiments; *P<0.05, **P<0.01 versus control (CTL). 
 
 
3.7 Role of the AMP-activated protein kinase (AMPK) in CYP2C-
induced angiogenesis 
 
The AMP-activated protein kinase (AMPK) was originally recognized as a regulator of 
cellular metabolism
 in response to hypoxia or vigorous contraction in muscle (Hayashi 
et al., 1998), but has recently been reported to play a role in the regulation of hypoxia-
and VEGF-induced angiogenesis (Nagata et al., 2003b).  Interestingly, the AMPK has 
also been implicated in the induction of CYP expression by phenobarbital (Rencurel et 
al., 2005).  We therefore determined the involvement of the AMPK in the VEGF-induced 
upregulation of CYP2C expression. 
Sol
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*
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To study the possible involvement of the AMPK in the VEGF-mediated increase in 
CYP2C expression HUVECs cells were stimulated with VEGF.  VEGF induced a rapid 
(within 5 minutes) phosphorylation of the AMPK on Thr172.  The response was biphasic 
with an initial peak at 10 minutes followed by a return to basal levels and a secondary 
but sustained AMPK activation after 24 hours (Figure 24A).   
To further characterize the involvement of VEGF on CYP2C expression cells were 
infected with the constitutively active and a dominant-negative AMPKα2 mutants.   
CYP2C RNA levels were increased in endothelial cells overexpressing the AMPKα2 
while the overexpression of a dominant negative AMPKα2 mutant prevented the VEGF-
induced increase in CYP2C RNA (Figure 24B), and protein (Figure 24C).  The CYP 
inducer phenobarbital (Schuetz, 2001) was used as a positive control to increase 
endothelial CYP2C expression (Figure 24C).  Phenobarbital also elicited an increased 
phosphorylation of AMPK in endothelial cells (Figure 24A). 
To downregulate AMPK expression in endothelial cells invading Matrigels implanted into 
mice an siRNA approach to downregulated murine AMPK levels was developed.   
Therefore, murine lung endothelial cells were treated with two different siRNAs directed 
against AMPK, a mixture of both siRNAs or scrambled siRNA and AMPK levels were 
assessed under control conditions.  Both siRNA tested as (siRNA1 and siRNA2) 
prevented AMPK expression (Figure 25A).   
Having identified two siRNAs to downregulate AMPK expression, Matrigels were 
impregnated with VEGF (150 ng/mL) in the absence and presence of either a control 
siRNA (GFP) or a mixture of siRNA1 and 2 against AMPK.   These Matrigels were then 
implanted in 8 week old female C57/BL6 mice (two per animal, one on each side of the 
spine) for a total of 7 days.  Thereafter, the infiltration of endothelial into the Matrigel 
plugs was assessed by immunohistochemistry (Figure 25B). 
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Figure 24.  Involvement of the AMPK in VEGF-induced CYP2C expression.  HUVECs were 
stimulated  with VEGF (30 ng/mL, 5 minutes to 48 hours) (A) Representative Western blots showing the 
time-dependent effect of VEGF on AMPK phosphorylation on Thr172.  Identical results were obtained in 
two additional experiments.  (B) Effect of AMPK mutants on CYP2C RNA expression.  HUVECs were 
infected with either a control virus or a dominant negative AMPK (DN) adenovirus 48 hours prior to 
stimulation with either solvent (Sol) or VEGF (30 ng/mL) for 6 hours.  CYP 2C mRNA was assessed by 
RT-PCR.  In some experiments endothelial cells were infected with a constitutively active AMPKα2 
mutant (CAα2) and CYP2C RNA levels were assessed after 24 and 48 hours.  (C) Effect of the dominant 
negative AMPK mutant on the VEGF-induced increase in CYP2C protein expression.  The bar graphs 
summarize data obtained in 3-4 independent experiments; *P<0.05 versus CTL. 
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Figure 25. SiRNA-mediated downregulation of AMPK in murine endothelial cells and in vivo.  (A) 
Mouse lung endothelial cells were transfected with different concentrations (20, 40 or 60 pM/L) of two 
different siRNAs, a mixture of both siRNAs directed against AMPK, scrambled siRNA (Scr) or treated with 
solvent (CTL) or GeneTrans transfection agent (GTII). (B) Matrigel was impregnated with VEGF (150 
nmol/mL) together with either a control siRNA or a mixture of siRNA 1 and 2 directed against AMPK and 
injected subcutaneously dorsally in mice.  After 7 days cryosections of the Matrigel plugs were stained for 
PECAM-1 (red).  Similar pictures were obtained in Matrigel plugs from 3 additional animals.    
 
 
3.8  Role of VEGF-induced CYP2C expression in cell proliferation and 
angiogenesis in vitro 
 
To assess the involvement of CYP epoxygenases in VEGF-mediated tube formation in 
vitro endothelial cell tube formation was assessed in an angiogenesis assay.  HUVECs 
were seeded on cell culture dishes coated with fibronectin and were treated with VEGF 
(30 ng/mL, 48 hours) in the absence and presence of the EET antagonist 14,15-EEZE 
(10 µmol/L), or the CYP epoxygenase inhibitor, MSPPOH (10 µmol/L). While endothelial 
cell tubes were apparent after 48 hours in the VEGF-treated cultures, the number of 
tubes formed was significantly attenuated in cells treated with either the EET antagonist 
or the CYP inhibitor (Figure 25A).   
bFGF is also known to play a role in the development and maintenance of the vascular 
system (Lee et al., 2000).  As one of the major growth factors involved in angiogenesis 
it is generally assumed to have very similar effects as VEGF, but it is unknown if Results 
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CYP2C is activated by one or several growth factors.  Therefore, to determine whether 
or not the effects observed were specific to VEGF-activated signalling an fibrin gel 
based angiogenesis assay was performed using bFGF as an angiogenic stimulus. In 
the latter case, interfering with CYP generation and EET activity was without effect on 
the ability of the growth factor to stimulate tube formation (Figure 26A).   
To determine the specificity of the effects described we ensured that EEZE did not 
interfere directly with VEGF signalling.  We assessed the effect of the EET-antagonist, 
14,15-EEZE, on the phosphorylation of the VEGF receptor-2.  Stimulation with VEGF 
resulted in the rapid and pronounced tyrosine phosphorylation of the VEGF receptor as 
assessed by Western blotting, but EEZE had no effect on either the basal- or VEGF-
stimulated phosphorylation of the receptor (Figure 26B). 
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Figure 26.  Effect of CYP inhibition and EET antagonism on VEGF-induced endothelial cell tube 
formation and receptor phosphorylation.  (A) Endothelial cell tube formation was assessed in 
response to VEGF (30 ng/mL) or bFGF (30 ng/mL) in the absence and presence of solvent (Sol; DMSO, 
0.01%), the EET antagonist 14,15-EEZE (EEZE, 10 µmol/L) or the CYP2C inhibitor MSPPOH (MS, 10 
µmol/L). Four representative photographs showing the effect of VEGF in the absence and presence of 
EEZE and MSPPOH are shown. The bar graph summarizes data obtained in 3-7 independent 
experiments; *P<0.05, **P<0.01 versus Sol. (B) Lack of effect of EEZE on the basal VEGF (30 ng/mL, 20 
minutes)-induced phosphorylation of the VEGFR2 receptor in phospho-tyrosine immunoprecipitates (IP) 
from VEGFR2 overexpressing porcine endothelial cells.  
 
The results obtained show that EETs are indeed involved in the angiogenic response 
mediated by VEGF and that this response seems to be specific and not to be mimicked Results 
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by bFGF.  However to more directly assess the impact of CYP2C on VEGF-induced 
endothelial cell sprouting in vitro a collagen-based spheroid assay was performed and 
combined with a previously described antisense oligonucleotide approach (Fisslthaler et 
al., 1999).  In this three-dimensional in vitro angiogenesis assay antisense 
oligonucleotides were used to downregulate CYP2C expression in endothelial cells that 
were treated at the same time with VEGF.  As expected VEGF (30 ng/mL, 24 hours) 
stimulated endothelial cell sprouting.  However, transfecting endothelial cells with 
CYP2C antisense oligonucleotides 14 hours before generating the spheroids markedly 
attenuated VEGF-induced sprouting (Figure 27).  To exclude any unspecific effects 
mediated by the transfection reagent CYP2C sense oligonucleotides were used as a 
control and did not interfere with the response observed in untransfected cells. 
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Figure 27.  Effect of inhibiting CYP2C expression on VEGF-induced endothelial cell sprouting.  
Sprouting activity in endothelial cell spheroids treated with solvent (PBS, 0.3%) or VEGF (30 ng/mL, 24 
hours).  HUVECs were infected with either control (CTL) or CYP2C9 adenoviruses and transfected with 
CYP2C sense (Se) or antisense (As) oligonucleotides.  After 24 hours, spheroids were formed and 
seeded into a collagen gel after an additional 24 hours.  Sprouting was assessed after 48 hours in the gel.  
The bar graph summarizes data obtained in 3-5 independent experiments; *P<0.05, **P<0.01 versus Sol, 
$P<0.05 versus VEGF stimulation in cells treated with Se oligonucleotides. 
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3.9  Role of VEGF-induced CYP-derived EETs in angiogenesis in vivo 
 
To assess the role of CYP-derived EETs on VEGF-induced angiogenesis in vivo, we 
used Matrigel plugs impregnated either with solvent, VEGF, the EET antagonist, 14,15-
EEZE or a combination of both and injected one dorsally on each side of the spine in 8 
week old female C57/BL6 mice.  As described earlier cryo sections of frozen plugs were 
stained for endothelial cells with PECAM-1 and smooth muscle cells with α-actin. 
Under the experimental conditions employed, endothelial cells (PECAM-1) and a few 
sparse smooth muscle cells/pericytes (α-actin) were detected in the VEGF-impregnated 
plugs after 14 days, only a few endothelial cells and no smooth muscle cells/ pericytes 
were detected in the solvent- or 14,15-EEZE-containing plugs. However, 14,15-EEZE 
almost completely abolished the angiogenic effect of VEGF when both were applied in 
combination (Figure 28). 
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Figure 28.  Effect of 14,15-EEZE on VEGF-induced angiogenesis in vivo.  Endothelial cell migration 
into Matrigel plugs impregnated with either solvent (DMSO, 0.1%, CTL), VEGF (150 ng/mL), the EET 
antagonist 14,15-EEZE (100 µmol/L) or the combination of both VEGF and 14,15-EEZE and injected 
subcutaneously in mice.  Images were taken after sectioning and immunostaining for PECAM-1 (red) and 
α-actin (green).  The bar graphs summarize data obtained in 4-10 independent experiments; *P<0.05, 
***P<0.001 versus the appropriate solvent (Sol) in the absence of EEZE, §§§P<0.001 versus VEGF. 
 
Our previous in vitro data indicated that the EET antagonist 14,15-EEZE selectively 
interfered with VEGF activated angiogenesis.  However, in vitro angiogenesis assays Results 
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focus on the proliferative and migratory processes of the angiogenic response where 
only endothelial cells, but no pericytes/smooth muscle cells are involved.  To 
demonstrate that the effect of 14,15-EEZE was also specific for VEGF in vivo, the same 
assay was repeated using Matrigel plugs impregnated with bFGF alone or in 
combination with 14,15-EEZE.  While bFGF clearly induced endothelial cell invasion of 
the plugs, this effect was insensitive to the EET antagonist (Figure 29). 
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Figure 29.  Effect of 14,15-EEZE on bFGF-induced angiogenesis in vivo.  Endothelial cell migration 
into Matrigel plugs impregnated with either solvent (Sol), bFGF (150 ng/mL), the EET antagonist 14,15-
EEZE (100 µmol/L) or the combination of both bFGF and 14,15-EEZE injected subcutaneously in mice.  
Images were taken after sectioning and immunostaining for PECAM-1 (red) and α-actin (green) and 
scored as the vessel formation index (see methods). The bar graphs summarize data obtained in 4-10 
independent experiments; *P<0.05, ***P<0.001 versus the appropriate solvent (Sol) in the absence of 14-
15-EEZE. 
 
At this point it was unclear if impregnation of Matrigel plugs with EETs could mimic the 
effect seen with VEGF.  Therefore to verify the role of EETs in angiogenesis in vivo and 
to compare the consequence of VEGF and 11,12-EET in the generation of vessel-like 
structures, the Matrigel plug assay was repeated. In plugs that contained 11,12-EET,  
tube-like structures of endothelial cells covered with smooth muscle cells were 
detectable, whereas in the VEGF-impregnated plugs only endothelial tubes were 
detectable.  Moreover the latter were not covered by smooth muscle cells (Figure 30) or 
pericytes.  Results 
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Figure 30.  Comparison of the effects of VEGF and 11,12-EET on vessel stabilization in vivo.   
Matrigel plugs were injected subcutaneously in mice.  After 14 days plugs impregnated with either VEGF 
(150 ng/mL) or 11,12-EET (10 µmol/L) were harvested and processed for immunostaining.   
Representative images showing endothelial cell (PECAM-1 staining, red) and smooth muscle/pericyte (α-
actin, green) content and scored as the stabilized vessel formation index (see methods). The bar graphs 
summarize data obtained in 4-10 independent experiments; *P<0.05 versus the appropriate control 
(CTL). 
 
As smooth muscle cell covered tube-like structures were detectable in EET-
impregnated plus and recruitment of mural cells is essential for vessel stabilization an 
obvious point to address was the functionality (i.e. perfusion) of these structures.   
Therefore, to assess whether or not those vessel like structure were functional isolectin 
was injected through the tail vein of mice before they were sacrificed.  As reported 
above, the addition of VEGF to the Matrigel significantly increased the number of 
endothelial cells detected in the plugs after 14 days, and, again little or no smooth 
muscle cells/pericytes could be detected.  Consistent with the formation of unstable 
endothelial tubes, we found no evidence of perfusion of the VEGF-treated plugs as we Results 
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were unable to detect significant isolectin in the plugs.  The situation was clearly 
different in plugs impregnated with 11,12-EET in which we detected a significant 
number of endothelial cell-containing structures surrounded by α-actin expressing cells.  
Moreover, isolectin was detected in all of the 11,12-EET-containing plugs following 
injection into the tail vein.  No isolectin signal was detected in the control plugs 
recovered from the same animals (Figure 31).  These findings confirm dat presented in 
figure 18 in which we reported significant haemoglobin levels in EET-containing plugs.   
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Figure 31.  Demonstration of functional vessels in 11,12-EET-containing Matrigel plugs.  Images 
were made after injection of isolectin through the tail vein, sectioning and immunostaining for isolectin 
(turquoise), PECAM-1 (red) and α-actin (green). The number of perfused vessels in each plug was 
scored as the vessel formation index (see methods). The bar graph summarizes data obtained in plugs 
from 3 (5 images per plug) mice per stimulation; **P<0.01 versus Sol. 
 
To verify these observations the plugs were subjected to blood flow analysis using 
contrast-enhanced ultrasound measurements. Looking at the time-dependent Results 
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accumulation of contrast agent, significantly higher peak enhancement was found in 
11,12-EET-impregnated plugs than in control plugs in the same animals (Figure 32).  
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Figure 32.  Ultrasound analysis of Matrigel perfusion in vivo.  Solvent (Sol, DMSO, 0.01%) and 
11,12-EET (10 µmol/L)-impregnated Matrigel plugs were implanted into mice (dorsal, one plug on each 
side of the spine) and blood flow was determined by ultrasound after 14 days. The representative images 
show the accumulation of contrast agent in the Sol- and EET-containing plugs 5, 10, 15 and 20 seconds 
after injection. The bar graph summarizes data obtained using 4 mice; *P<0.05 versus Sol. 
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4. Discussion 
 
The results of the present investigation document the importance of CYP2C-derived 
EETs at different stages of the angiogenic response and highlight the intimate 
relationship between EET and key components of the regulation of proliferation and 
angiogenesis, i.e. EphB4 and VEGF.   
We found that CYP2C9 overexpression and enhanced EET production lead to EphB4 
upregulation via the Akt/PI3K pathway and that this effect in vitro as well as in situ is 
mimicked by the epoxygenase metabolite 11,12-EET.  Moreover, moving away from 
overexpression studies, we found that VEGF stimulation increases CYP2C9 expression 
and subsequent EET-production by a mechanism that relies on the activation of the 
AMPK.  Furthermore, it was possible to demonstrate in vitro that EphB4 as well as 
VEGF play a critical role in the angiogenic response initiated by CYP2C9 as inhibition of 
both pathways resulted in decreased endothelial sprouting.  In vivo the significance of 
the in vitro findings was assessed in a Matrigel plug assay in which the downregulation 
of EphB4 as well as the use of an EET-antagonist resulted in decreased infiltration of 
endothelial cells as well as smooth muscle cells into the EET-impregnated plug.  Thus,  
our findings characterize 11,12-EET not only as an angiogenic stimulus that plays a role 
in the modulation of signalling pathways and events that lie down as well as upstream of 
CYP2C activation, but also as a second messenger for a growth factor, i.e. VEGF,   
already well known to be involved in the angiogenic response.  Moreover, our findings 
indicate that CYP2C-derived EETs have the potential to do much more than promote 
cell proliferation and tube formation and reveal an important role of EETs in the vascular 
maturation process that could have potential significance in the treatment of a number 
of diseases such as cancer and diabetic retinopathy. 
 
 
4.1  Role of EphB4 and VEGF in CYP2C-induced angiogenesis 
 
In general very little is known about the exact mechanisms involved in the angiogenic 
response initiated by CYP2C-derived EETs.  It has for example been shown that CYP-
derived EETs are able to stimulate matrix metalloproteases and thereby transactivate 
the EGF receptor resulting in the activation of the serine threonine kinase Akt and an Discussion 
 
  59
enhanced expression of cyclin D1 (Michaelis et al., 2003).  However, no studies have 
yet elucidated in any great detail the involvement of any other major growth factors.   
Eph receptor tyrosine kinases and their ligands, the ephrins, are involved in a number of 
processes that are crucial for several molecular and cellular mechanisms that control 
the formation of the vascular network and its remodelling (Holder and Klein, 1999).  Up 
till now their function has mostly been studied in the nervous system where the 
Eph/ephrin system is involved in the development of both the central and peripheral 
neural system (O'Leary and Wilkinson, 1999), but recently a number of studies also 
demonstrated a role of Ephs and their ligands in the development of the cardiovascular 
system (Wang et al., 1998; Adams et al., 1999).  Although the exact consequences of 
Eph-ephrin interactions and the associated forward and reverse signalling on 
endothelial cell function in adult animals are not clear, it has been proposed that the 
Eph-ephrin signals are likely to play a role in the spatial organization of 
developing/remodelling vasculature (Füller et al., 2003).   
Our findings indicate that CYP2C9-overexpression results in an upregulation of EphB4 
in HUVECs as well as in the Matrigel plug in mice in vivo.  The fact that this 
upregulation is a direct consequence of increased CYP2C expression was confirmed 
using the epoxygenases inhibitor MSPPOH.  However, metabolism by CYP 
epoxygenases not only results in the generation of EETs, but also in the production of 
reactive oxygen species (Fleming et al., 2001b).  Although it has been shown that 
EphB4 is involved in tumorigenesis (Noren and Pasquale, 2007) and also that reactive 
oxygen species play a role in the signalling pathways involved in tumour progression 
(Wu, 2006), the increase in EphB4 expression elicited by CYP2C9 could be mimicked 
by one of the archidonic acid epoxides, i.e. 11,12-EET.  Further evidence was provided 
in situ where stimulation of mesenteric arteries and veins with 11,12-EETs also resulted 
in increased EphB4 expression, making it unlikely that CYP2C-derived reactive oxygen 
species underlie the effects observed.   
Regulation of Eph receptor expression occurs at many levels that include induction of 
transcription and internalization of the receptor-ligand complex.  CYP2C9-mediated 
upregulation could be detected at the transcriptional level as the EphB4 promoter was 
activated in CYP2C9 overexpressing cells.  One of the transcription factors that has 
emerged a major regulator of EpB4 expression is homeobox A9 (Bruhl et al., 2004).  
However, CYP2C9 overexpressing cells activated the EphB4 full length promoter 
construct to the same extent as a promoter construct with mutation of the putative Discussion 
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HoxA9 binding site (data not shown), indicating that homeobox A9 is not essential for 
the CYP2C-mediated activation of EphB4.   
A number of EET-mediated effects in vitro and in vivo can be attributed to an increase in 
the intracellular concentration of cAMP and the subsequent activation of PKA.  It has for 
example been shown that 11,12-EETs elicit afferent arteriolar vasodilation via activation 
of adenylate cyclase and PKA (Imig et al., 1999).  Furthermore interendothelial 
communication via gap-junctions is mediated by a similar mechanism (Popp et al., 
2002).  In endothelial cells overexpression of CYP increases cAMP levels, stimulates 
the cAMP-response element-binding protein, and enhanced cyclooxygenase-2 (COX-2) 
promoter activity which contributes to the EET-mediated angiogenic response 
(Michaelis et al., 2005).  However, in the present study a specific PKA inhibitor had no 
effect on CYP2C-induced EphB4 expression, indicated that another signalling 
mechanism must be responsible. 
The protein kinase Akt is a central signalling molecule involved in cell survival, 
proliferation, tumour growth and angiogenesis (Jiang and Liu, 2008) and activation of 
the Akt/PI3K pathway has been reported to play a role in the regulation and signalling of 
Eph receptors.  For example, EphB4 mediated proliferation and migration of 
microvascular endothelial cells is mediated by the Akt/PI3K-pathway (Steinle et al., 
2002) and PI3K activity can be increased in HUVECs by Eph stimulation (Maekawa et 
al., 2003).  One EET-activated pathway certainly linked to angiogenesis is the 
transactivation of the EGF receptor and subsequent Akt activation (Michaelis et al., 
2003).  Although, EETs probably also activate Akt via alternative mechanisms, the 
consequences are the same and 11,12-EET induces the phosphorylation and therefore 
inhibition of the forkhead factors FoxO1 and FoxO3a and subsequently a decrease in 
the expression of the cyclin-dependent kinase inhibitor p27
kip1 (Potente et al., 2002).  
The findings of the present study confirm activation of Akt by the CYP2C-metabolite 
11,12-EET and link this to the expression of EphB4 as CYP2C-overexpression resulted 
in both increased Akt phosphorylation and this was paralleled by an increase in EphB4 
expression.  In addition, inhibition of the Akt/PI3K -pathway as well as suppression of 
Akt activity using a dominant negative mutant resulted in decreased EphB4 expression 
levels.  However, the exact mechanisms by which CYP2C-derived EETs activate the 
Akt/PI3K pathway resulting in increased EphB4 expression still need to be elucidated.  
The p85 regulatory subunit of PI3K has been reported to be constitutively associated 
and phosphorylated by other growth factor receptors such as VEGFR-2, resulting in Discussion 
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increased PI3K and Akt activities in vivo (Gerber et al., 1998; Ilan et al., 1998) and it 
certainly cannot be excluded that a similar mechanisms might be relevant in the EET-
mediated angiogenic response. 
The differential expression of Ephs and ephrins in arteries and veins as well as the 
differential biological actions in vascular development raise a number of questions and 
are discussed very controversially.  Traditionally, ephrinB2 was thought to be expressed 
in arterial endothelial cells whereas EphB4 was restricted to venous endothelial cells 
(Gerety et al., 1999; Shin et al., 2001).  Although a role for EphB4 in arterial endothelial 
cell migration and tube formation has been proposed by others (Salvucci et al., 2006) 
these findings are somewhat controversial.  Indeed, EphB4 is still predominantly 
classed as a negative regulator of blood vessel branching and vascular network 
formation, and is generally accepted to switch the vascularisation program from 
sprouting angiogenesis to circumferential vessel growth (Erber et al., 2006).  This 
implies that large vessels with few branches would be expected to form in vessels 
expressing EphB4.  However, the unconditional classification of ephrinB2 as an arterial 
and EphB4 as a venous marker no longer appears to be strictly the case, and although 
the arterial expression of ephrinB2 has been confirmed in many different models (Shin 
et al., 2001) EphB4 expression has also been repeatedly detected in arterial endothelial 
cells, (Hall et al., 2002; Diehl et al., 2005).  For example EphB4 expression has been 
detected in remodelling rat mesenteric microvessels and particularly in capillary sprouts 
(Taylor et al., 2007), suggesting that the classical view of receptor ligand distribution 
may have to be adjusted.  In the present study, atypical EphB4 expression was 
detected and the strongest EET-induced expression of EphB4 was observed in isolated 
murine mesenteric arteries, even though there was no detectable expression of the 
protein in the endothelium of freshly isolated vessels.  In contrast, EphB4 was 
abundantly expressed in mesenteric venous endothelial cells but was not upregulated 
by EET treatment.  In endothelial cells, it seems fair to state that expression of the 
EphB4 ligand ephrinB2 is determined by microenvironmental
  conditions and by 
stimulation with VEGF rather than being an intrinsic endothelial cell
  differentiation 
marker (Korff et al., 2006).  Based on the results of this investigation it could be 
speculated that under certain conditions, for example in situations of increased CYP2C9 
expression or direct application of the metabolite 11,12-EET, EphB4 expression may no 
longer be solely determined as the venous endothelial cell phenotype,
 but can rather be 
influenced by alternative determinants.  Arteriovenous differentiation has been Discussion 
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characterized as
 a primarily genetically driven process during development (Moyon et 
al., 2001), but the findings of this study stress the importance of the control of vascular 
homeostasis by microenviromental cues.   
EphrinB2 forward signalling through its receptor EphB4 induces cell detachment and 
inhibits cell spreading, migration,
 and proliferation, whereas EphB4 reverse signalling 
induces cell
 attachment, spreading, and migration (Hamada et al., 2003).  EphrinB2-
expressing angiogenic endothelial cells that are activated by EphB4 promote migration 
and this reverse ephrinB2 signalling therefore acts pro-adhesively and induces 
sprouting angiogenesis (Füller et al., 2003).  EphrinB ligands are known to be activated 
by several growth factors in vitro and in vivo  such as the fibroblast growth factor 
receptor (FGFR) (Chong et al., 2000), but it still remains to be clarified how this can 
affect reverse signalling and Eph receptor activation.  As EETs can affect a number of 
angiogenic signalling cascades, and stimulation of endothelial cells with the CYP 
metabolites results in receptor phosphorylation, EET are certainly another potential 
candidate for EphB4 ligand activation.  Classically, phosphorylation and signalling 
occurs after binding of the ligand ephrinB2 to its receptor.  It would therefore be 
expected that an alteration in EphB4 expression patterns by EETs would also be 
accompanied by altered ephrinB2 expression.  It has for example been shown that 
hypoxia leads to upregulation of the ligand as well as its receptor in a mouse skin flap 
model (Vihanto et al., 2005).  However, even though CYP2C overexpression in 
endothelial cells resulted in EphB4 phosphorylation and therefore activation, ephrinB2 
expression levels were not altered.  Therefore, in the experimental settings used EphB4 
expression was independent of the expression of its ligand, but dependent on EET in a 
concentration-and time-dependent manner.  Consequently, increased reverse ligand 
signalling cannot be accounted for the increased angiogenic activity, because under the 
conditions employed in our study CYP activation does not result in increased ephrinB2 
expression.  Thus, in specific situations such as EET-mediated angiogenesis, EphB4 
also seems to be implicated in sprouting angiogenesis.  Indeed, in a collagen based 
tube formation assay the downregulation of EphB4 expression in CYP2C9-
overexpressing cells markedly attenuated the angiogenic response.  Furthermore, in 
vivo the vessels that formed within Matrigel plugs impregnated with 11,12-EET 
expressed EphB4, and endothelial cell infiltration into Matrigel was prevented by its 
downregulation.  Taken together, our observations indicate that EphB4 may also be 
implicated in capillary sprouting in specific situations, such as angiogenesis associated Discussion 
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with inflammation.  Certainly, there are a number of preliminary observations, e.g. in the 
mouse ear (T. Korff, unpublished data, 2007), that support this hypothesis. 
The regulation of angiogenesis by hypoxia is an important component of homeostatic 
mechanisms that link the vascular oxygen supply to cellular and systemic responses 
(Hickey and Simon, 2006) and an important stimulus for expansion of the vascular bed.  
Cells are oxygenated by simple diffusion of oxygen, but when diffusion distances from 
the existing vascular supply increase and tissue size expands beyond the limit of 
oxygen diffusion, hypoxia triggers vessel growth.  These mechanisms are in part 
governed by the activation of the hypoxia-inducible transcription factors HIF-1 and HIF-
2.  The promoter region of the CYP2C8/9 genes contain hypoxia-responsive elements 
and a number of CYP2C isoforms are sensitive to changes in oxygen tension (Marden 
et al., 2003; Pokreisz et al., 2006; Michaelis et al., 2008).  Our group has previously 
reported that CYP induction by hypoxia contributes to cell proliferation and 
angiogenesis in vitro as well as in vivo (Michaelis et al., 2005a).  Therefore, it seemed 
logical to hypothesize a potential link between VEGF- and EET-signalling since the 
induction of VEGF by hypoxia and the role of the latter growth factor in hypoxia-induced 
cell migration is well documented (Ferrara and vis-Smyth, 1997). 
Stimulation of endothelial cells with VEGF increased CYP2C expression and EET 
production and preventing the induction or inhibiting the activity of CYP2C significantly 
attenuated the angiogenic response to VEGF.  These observations go in a similar 
direction as the recent report indicating that another CYP-derived metabolite of 
arachidonic acid, namely 20-HETE, can, at least acutely, be activated by VEGF in 
pulmonary arteries (Guo et al., 2007). 
The relevance of VEGF and its receptors in vascular development has been 
demonstrated in various knockout animals.  For example, the deletion of either VEGFR1 
(Shalaby et al., 1995) or VEGFR2 (Fong et al., 1995) has proven to be lethal due to 
abnormalities in vessel formation.  Consequently, it appears both receptors are 
essential for the development of the vasculature in the mouse embryo.  Analysis of 
VEGFR signalling has led to the conclusion that although affinity for VEGF binding is 
approximately ten-fold higher for VEGFR1 than for VEGFR2, it is the latter protein that 
conveys the VEGF-mediated effects in endothelial cells (Gille et al., 2001).  However, in 
our studies VEGF was able to increase the activity of the CYP2C9 promoter in cells 
expressing either VEGFR1 or VEGFR2, indicating that the VEGF-mediated CYP2C Discussion 
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activation does not seem to be restricted to one of the two receptors and that under the 
conditions employed activation of both receptors is essential for the VEGF-mediated 
angiogenic response. 
One of the most important functions of VEGF is certainly its essential role in vivo in 
embryonic vasculogenesis and the promotion of angiogenesis by stimulating endothelial 
cell survival and growth (Carmeliet et al., 1996; Ferrara et al., 1996).  In the Matigel plug 
assay in mice, VEGF resulted in increased infiltration of endothelial cells and a few 
sparse smooth muscle cells into the plug.  This is in line with the in vitro findings in a 
collagen gel spheroid assay and confirms the (patho)physiological significance of VEGF 
for endothelial cell sprouting and angiogenesis. 
VEGF has previously been demonstrated to activate the AMPK in endothelial cells 
(Reihill et al., 2007) and activation of the α2 subunit of the kinase has been linked to 
endothelial cell migration and angiogenesis (Ouchi et al., 2004).  Moreover, AMPK 
signaling has been identified as a regulator of angiogenesis that is specifically required 
for hypoxia-induced endothelial cell migration and differentiation (Nagata et al., 2003a).  
Interestingly, activation of the AMPK by phenobarbital is reported to increase the 
expression of CYP2B in chicken and human hepatocytes (Blattler et al., 2007).   
Therefore, the relevance of AMPK in the VEGF-induced increase in CYP2C expression 
was assessed.  Consistent with the previous reports (Reihill et al., 2007; Shindo et al., 
2007), VEGF and phenobarbital both stimulated the phosphorylation of the AMPK in 
endothelial cells and both stimuli increased CYP2C expression. Moreover, the 
overexpression of a dominant negative AMPK mutant significantly reduced VEGF-
induced CYP2C expression.  Although the involvement of the AMPK in the VEGF-
induced expression of CYP2C could clearly be demonstrated, the complete molecular 
mechanism is still unclear.  It is however likely that LKB1, one of the upstream kinases 
of AMPK might be involved (Blattler et al., 2007) since it phosphorylates and activates 
the AMPK subunit at Thr-172 as recently shown in human hepatoma cells (Rencurel et 
al., 2005), as well as in primary mouse and human hepatocytes (Rencurel et al., 2006).  
Another potential candidate is the TGFβ-activated kinase 1 (TAK1) that has been 
shown to play an important role in AMPK activation in the heart (Xie et al., 2006).   
Indeed, TAK1 mutant embryos have defects in the developing vasculature of the 
embryo (Jadrich et al., 2006).  As it has been shown that TAK1 signals through the 
MAPK pathway (Shirakabe et al., 1997; Hanafusa et al., 1999) that activates several Discussion 
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signalling molecules, including p38 and JNK, and CYP2C influences JNK expression 
levels (Potente et al., 2002), regulation of TAK may also be involved in the CYP2C-
mediated angiogenic response mediated by VEGF.   
Although EETs have been suggested to act as second messengers in the EGF-
activated signalling cascade (Chen et al., 1999), not all growth factors are able to 
upregulate CYP epoxygenases.  For example, although the EET antagonist, 14,15-
EEZE, almost abolished VEGF-induced endothelial tube formation in vitro and in vivo, it   
did not affect the angiogenic response induced by bFGF.  VEGF and FGF both exert 
their effects via specific binding to cell surface-expressed receptors and their activiation 
results in similar downstream signal transduction pathways.  Furthermore, VEGF and 
FGF share a number of downstream targets including MAPK and PI3K that have also 
been identified in signalling cascades activated by EETs.  The two angiogenic growth 
factors, bFGF and VEGF, can for example be distinguished on the basis of their 
requirement for Src kinase activity (Eliceiri et al., 1999).  While Src family kinases seem 
to serve compensatory roles during embryogenesis and angiogenesis, VEGF, but not 
bFGF-mediated angiogenesis requires its activity for endothelial cell survival.  Therefore 
the AMPK-mediated upregulation of CYP2C via VEGF seems to be another growth 
factor specific phenomenon.  Furthermore, to date a bFGF mediated activation of AMPK 
has not been reported.  Consequently, VEGF and bFGF might potentiate somewhat 
different biological effects during blood vessel formation.  This would also tie in with 
observations that blood vessel formation and regeneration in different organs may differ 
as for example neovascularisation in the retina has been linked to VEGF expression 
(Miller et al., 1994), while cutaneous wound repair rather seems to be bFGF-dependent 
(Takenaka et al., 1997). 
The VEGF-activated signalling cascade leading to angiogenesis has previously been 
linked to an increase in the formation of reactive oxygen species (Colavitti et al., 2002).  
Although the NADPH oxidase has been implicated as the source of these radicals 
(Ushio-Fukai et al., 2002), it should be noted that the activation of CYP2C 
epoxygenases also results in the generation of superoxide anions (O2
-) in sufficient 
amounts to alter the bioavailability of nitric oxide and the expression of adhesion 
molecules (Fleming et al., 2001b).  To verify whether EETs rather than CYP2C-derived 
reactive oxygen species were involved in mediating VEGF-induced angiogenesis, the 
EET antagonist, 14,15-EEZE was employed.  In contrast to the epoxygenase inhibitors 
MS-PPOH and sulfaphenazole, as well as the CYP2C antisense treatment, which Discussion 
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attenuate the production of all the CYP2C products (EETs, 20-HETE and O2
-), 14,15-
EEZE antagonizes only the effects of EETs without interfering with those of 20-HETE 
(Gauthier et al., 2002) or
 the production of O2
- by CYP2C enzymes (U.R. Michaelis, 
unpublished observations).  We found that 14,15-EEZE inhibits VEGF-induced tube 
formation in vitro and angiogenesis in vivo, indicating that EETs and not reactive oxygen 
species
 were responsible for the effects observed.  Moreover, there was no detectable 
effect of VEGF on 20-HETE formation, indicating that 20-HETE does not contribute to 
angiogenesis under the conditions studied.   
 
 
4.2  Role of EETs in vessel maturation 
 
Angiogenesis consists of endothelial cell sprouting as well as vascular maturation, 
which includes the recruitment of perivascular cells, smooth muscle cells for large and 
pericytes for small vessels.  In recent years, extensive efforts have been made to gain 
understanding into the molecular mechanisms of this process.  Several angiogenic 
growth factors that regulate endothelial sprouting have been identified, but little attention 
has been focused on vascular maturation.  One prerequisite for the formation of a 
functional vasculature system is regulated by communication between endothelial cells 
and smooth muscle cells (Hirschi and D'Amore, 1996; Hirschi and D'Amore, 1997; 
Hungerford and Little, 1999).  Interaction between these two cell types in the blood 
vessel wall has a critical role in the regulation of vascular formation, stabilization, 
remodelling and function.  Equally, failure of these interactions has been demonstrated 
in a number of mouse models resulting in severe and often lethal vascular defects 
(Armulik et al., 2005).  Abnormal interactions of endothelial cells and pericytes are 
involved in a number of human pathological conditions, including tumour angiogenesis, 
diabetic microangiopathy, ectopic tissue calcification, stroke and the dementia 
syndrome cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy) (CADASIL) (Bergers et al., 2003; Hammes, 2005).   
In the present study, we demonstrated that 11,12-EET activates several signaling 
molecules (i.e. AMPK and PI3K) that are involved in processes resulting in the 
recruitment of pericytes/smooth muscle cells and stabilization of blood vessels.  In the 
Matrigel Plug assay in vivo impregnation of plugs with 11,12-EET stimulated the Discussion 
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formation of smooth muscle cell stabilized and perfused blood vessels.  This was 
evidenced by the injection of isolectin into the tail vein which resulted in the 
accumulation of isolectin close to vessels in the Matrigel plug.  Moreover, by ultrasound 
measurement, blood flow could be demonstrated through the EET-impregnated plugs 
as there was a significant accumulation of contrast agent compared to the control plug.  
In contrast, but as expected on the basis of previous reports (Zacchigna et al., 2007), 
VEGF stimulated endothelial cell recruitment into the matrix material but only a few α-
actin-expressing cells could be detected.  Moreover, it was not possible to detect 
isolectin staining in VEGF-containing plugs.  
In endothelial cells, gap junctions are important for homotypic (endothelial to 
endothelial) and heterotypic (endothelial to e.g. smooth muscle cell) communication 
(Dejana et al., 1995).  Those gap junctional communications, at least between 
endothelial cells, can be activated by a CYP2C and cAMP-dependent pathway (Popp et 
al., 2002).  Because it has been shown that junctional coupling may be important for the 
coordination of migration and repair during angiogenesis (Pepper et al., 1989) 
heterotypic gap junctional communication might be one possible underlying mechanism 
for the recruitment of smooth muscle cells/pericytes to endothelial cell tubes in EET-
impregnated plugs.  This would be consistent with reports that the connexin43 knockout 
mouse dies at birth due to severe defects in coronary vasculogenesis/angiogenesis   
(Walker et al., 2005). 
Pericytes are believed to be able to transdifferentiate into vascular smooth muscle cells 
and vice versa in conjunction with vessel growth and remodelling (Nehls and 
Drenckhahn, 1993).  Much of the current knowledge about the signalling between 
endothelial cells and pericytes/smooth muscle cells comes from genetically modified 
mouse models.  In those studies it has been demonstrated that the different cell types 
are interlinked to a great extent and this means that defects in one cell type have 
mandatory consequences for the other resulting in increasingly intricate signalling 
pathways where all cell types involved have to be taken into consideration.  It has for 
example been shown that endothelium-derived TGF-β is important for pericyte 
differentiation and that activation of latent TGF-β is dependent on endothelial-pericyte 
contact (Carvalho et al., 2004).   
Although there has been substantial progress in the identification of the molecular 
details of endothelial – pericyte/smooth muscle cell interactions, many aspects of the 
process are still incompletely understood.  In the course of this study 11,12-EETs were Discussion 
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identified as positive regulators of mural cell recruitment.  Evidence from Matrigel plug 
assays suggested that EETs are indeed a critical determinant of pericyte/smooth 
muscle cell recruitment as mature, perfusable endothelial tubes covered by 
pericytes/smooth muscle cells were not detectable in plugs impregnated with other 
growth factors, such as VEGF.  This was at first sight surprising as we have also shown 
that VEGF stimulation resulted in increased EET-production.  However, in the course of 
this study it was not investigated if VEGF had any effect on the activation of sEH, the 
enzyme metabolising EETs.  Moreover, in contrast to the impregnation of a Matrigel 
plug which creates an EET- gradient, constant EET production by VEGF might not be 
high enough to elicit pericyte recruitment.   
Although our data indicate a role for EETs in vascular maturation, it is still not clear if 
this effect is directly mediated by CYP2C9-derived EETs or if the epoxides stimulate 
secondary responses that involve other signalling molecules.  There are a number of 
signalling molecules that have been shown to be essential for the recruitment of 
pericytes/smooth muscle cells to endothelial tubes.  For example, the G protein-coupled 
receptor S1P1 is expressed both in smooth muscle and endothelial cells and is known to 
act within the latter to regulate vascular maturation (Allende et al., 2003).  The receptor 
may well be relevant for CYP-mediated angiogenesis as a recent report suggests that 
the activation of sphingosine kinase-1, a key enzyme catalyzing the phosphorylation of 
sphingosine to sphingosine-1-phosphate, mediates the induction of endothelial cell 
proliferation and angiogenesis by EETs (Yan et al., 2008).  In conjunction with the 
findings of this study as well as data that S1P-mediated endothelial cell 
hyperpolarization can be abolished by the CYP epoxygenases inhibitor sulfaphenazole 
(unpublished data), this suggests a possible role of S1P1 as a second messenger in the 
recruitment of smooth muscle cells by EETs.  Although this hypothesis is interesting we 
have been unable to detect any substantial role of S1P1  receptor signalling in our 
experimental models (unpublished data).  There are a number of other signalling 
cascades, such as angiopoietin-Tie 2 and PDGF-B/PDGF-β, which have been 
implicated in mural cell development that could also play a role in EET-stimulated 
vascular maturation.  11,12-EET can for example inhibit the PDGF-induced migration of 
rat aortic smooth muscle cells (Sun et al., 2002), and this phenomenon correlates with 
increased intracellular cAMP levels.  Even though it is known that a number of effects 
observed in endothelial cells involve elevated cAMP levels, the effect observed in 
smooth muscle cells might not only be due to CYP-derived 11,12-EETs, but possibly to Discussion 
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one of the other regioisomers generated by the enzyme.  Responses also appear to be 
cell type-dependent as 11,12-EET stimulates migration in human kidney epithelial cells 
as well as in HUVECs (Cheng et al., 1999; Michaelis et al., 2005).   
 
 
4.3 The putative EET-receptor and the role of endogenous EET 
production and exogenous EET application in angiogenesis 
 
EETs are lipophilic molecules that can be released
 from the cells in which they are 
generated to exert paracrine
 effects.  However, in most cases the CYP metabolite is 
either conjugated or rapidly metabolized by the sEH (Newman et al., 2005).   
Consequently, extracellular EET levels are usually fairly low and it can be assumed that 
the metabolite exerts most of its effects as an intracellular second messenger.  This 
assumption certainly fits well with the role of EETs in regulating intracellular calcium 
concentration in endothelial cells (Fleming et al., 2007) and the fact that downregulation 
of CYP2C by antisense oligonucleotides markedly reduced the proangiogenic effect of 
VEGF.   
Even though we assume that the intracellular effects of EETs are the most important in 
the regulation of endothelial cell biology, it is clear that endothelial cells do release 
EETs under certain conditions and that endothelial cell-derived EETs can affect other 
cell types.  Autocrine responses are mediated by EETs that are either released from 
arachidonic acid or from intracellular phospholipids by PLA2 and can be recovered in 
the extracellular fluid.  They probably stay long enough within or in the close vicinity of 
cells to initiate the respective response.  Observations that radiolabeled EETs that are 
initially present in the endothelium accumulate in the extracellular fluid suggest that 
some of these EETs remain in the cytosol before they are released to the medium.  
Similarly EETs from the extracellular fluid can initiate paracrine effects.  They can for 
example be reincorporated into vascular smooth muscle cells or converted to DHETs in 
the cytosol (Zeldin et al., 1993).   
The initial step responsible for EET signalling is still largely unknown.  One potential 
mechanism might be activation of a putative EET receptor.  Other alternatives are less 
direct effects on lipid fluidity as EETs incorporate into the plasma membrane in order to 
associate with other molecules as for example PKA (Imig et al., 1999) or the ADP Discussion 
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ribosyltransferase (Li et al., 1999).  In favour of the concept of a specific EET receptor 
are reports that physiological actions of the epoxide are dependent on specific structural 
requirements, such as defined locations of the double bond.  Such ‘structure-activity’ 
interdependencies are certainly an indicator for a specific receptor and in bovine 
coronary arteries (Falck et al., 2003) modification of the epoxy oxygen or the carboxyl 
group had profound effects on the ability of the epoxides to induce relaxation (Gauthier 
et al., 2002c).  The identification of a functional EET antagonist (i.e. 14,15-EEZE) also 
fueled speculation on the existence of an EET receptor.  Perhaps the most exciting 
evidence to support the concept was the demonstration of a higly highly specific binding 
site in radioligand binding studies with labelled EETs in guinea pig monocytes (Wong et 
al., 2000).  Although the latter studies confirmed a previous report in  U937 cells (Wong 
et al., 1997) which contain a cell surface protein with a stereoselective binding site for 
14(R)-15(S)-EET, there has been disturbingly little progress in this area.  Recent effort 
has concentrated on finding a binding partner for the EETs among the orphan 
receptors.  Indeed, there is evidence that 11,12- and 14,15-EET binding activates the 
adenylyl cyclase, increases intracellular cAMP levels and activate PKA and the cAMP 
response element binding protein (Node et al., 2001; Spector and Norris, 2007); in other 
words all the ‘classic’ elements of a GαS-coupled receptor signalling cascade.  In 
addition, it was shown that the EET-stimulated activation of  BKCa-channels can be 
blocked by a GαS-specific G protein inhibitor (Li and Campbell, 1997).  These data 
suggest that EETs might initiate their signalling cascade through a membrane, GαS-
coupled receptor.  However, while some acute effects of EETs are PKA-dependent, in 
the present study neither the signaling pathway involved in the EET-mediated increase 
in EphB4 expression nor in the VEGF-mediated CYP2C upregulation involved the 
activation of PKA via increased cAMP levels.   
Alternatively it has been proposed that EETs can enter cells, either as a result of 
uptake, hydrolysis of EET-containing phospholipids or CYP-mediated production from 
arachidonic acid, and interact directly with intracellular effectors such as the fatty acid 
binding proteins, ion channels or transcription factors (e.g. PPARs) that elicit the 
functional response.   However, a lot of the data supporting this mechanism have been 
generated biochemically or in cell culture and up till now no conclusive evidence of 
intracellular interaction with such effector molecules has been generated in vivo.   
 
 Discussion 
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4.4  Relevance of this study 
 
In the past decade, effort has been made to further develop what has been termed 
‘therapeutic angiogenesis’, i.e. therapeutic strategies to promote the revascularization of 
ischemic tissues, or to inhibit angiogenesis in several diseases such as cancer, ocular, 
joint or skin disorders.  However, up till now most of the clinical trials testing the pro-
angiogenic potential of VEGF or bFGF have been disappointing as they failed to provide 
clear proof of effectiveness (Rajagopalan et al., 2003).  Furthermore, animal studies 
involving VEGF gene therapy have revealed that major complications can be associated 
with a growth factor monotherapy, for example VEGF gene therapy in mice and human 
leads to hemangioma (i.e. visible red skin lesion) and vascular leakage (Springer et al., 
1998).  Recent clinical studies with VEGF inhibitors have raised a number of questions 
regarding the selectivity and efficiency of these compounds and it is now clear that 
targeting endothelial cells and/or the principal growth factor VEGF alone may not be 
sufficient to eradicate malignant tumours or cure growth factor-related diseases.   
Consequently, a more attractive approach would maybe be either a combined treatment 
of anti-angiogenic agents with distinct complementary mechanisms or a ‘master gene 
therapy’; that is via genes capable of activating multiple angiogenic pathways and 
stimulating the expression of factors that promote not only angiogenesis, but also vessel 
maturation.  One of those master genes could be CYP2C as our data indicate the 
importance of 11,12-EET on (patho)physiological angiogenic processes.  At this point it 
is important to point out that CYP enzymes are not only expressed in endothelial cells 
and CYP2C as well as CYP2J enzymes have been detected in different tumour tissues 
(Yokose et al., 1999) and can induce tumour growth as well as promote metastasis 
(Jiang et al., 2005; Jiang et al., 2007).  It is therefore tempting to speculate that CYP 
enzymes might represent a new target for the treatment of tumour growth and therefore 
cancer therapy.  The findings of this study, together with a number of properties 
attributed to CYP2C9 may be a potential target for future gene therapy.   
CYP2C-derived EETs may play important roles in promoting invasion and metastasis of 
cancer through several mechanisms.  They are involved in the activation of many 
signalling pathways that can have both short term (cell proliferation, invasion and 
adhesion) and long term (gene expression) effects on carcinoma cells.  By interfering 
with molecules that have been demonstrated in other studies to be involved in 
carcinogenesis, such as EphB4 and VEGF, modulation of CYP2C expression may Discussion 
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involve down-regulation of metastatic suppressor genes, the up-regulation of metastasis 
enhancer genes and the activation of a variety of signalling cascades such as Akt/PI3K.  
Furthermore, the recent emphasis on the importance of the role of interactions between 
pericytes and endothelial cells raises a number of questions regarding many aspects of 
endothelial-pericyte communication.  It is for example far from clear how pericytes 
stabilize vessels and why this process fails in tumour vessels.  In the course of this 
study it became evident that EETs play a role in these interactions, but the precise 
molecular mechanisms as well as the exact relevance for physiology and pathology is 
still unclear.  Pharmacological inhibitors of some CYP isoforms have been identified as 
promising anti-cancer agents (Chun and Kim, 2003; Chong et al., 2007).  However, the 
majority of work published to-date has focused on the consequences of CYP inhibition 
on the bioavailability of anti-cancer agents, rather than determining the consequences 
of CYP inhibition per se.  
Beyond its potential use in oncology, there is certainly a role of EETs in the treatment of 
vascular diseases.  As mentioned previously, the EET/EDHF pathway is assumed to be 
a backup vasodilator mechanism that ensures vasodilatation in case of decreased NO 
bioavailability.  Consequently, cardiovascular diseases and CYP epoxygenases might 
be linked at two levels.  Although there is currently very little known regarding a 
potential role of CYP-derived EETs in human diseases, at least in animal models 
epoxygenase levels have been linked to hypertension (Spector and Norris, 2007).  It 
has for example been shown in studies focused on spontaneously hypertensive rats 
that EETs and sEH inhibition can affect blood pressure (Sellers et al., 2005).  Another 
point that should not be ignored is that most patients, especially those treated for 
cardiovascular diseases, receive more than one pharmacological agent over a long time 
period.  This is relevant since there are a number of drugs, such as  the Ca
2+ antagonist 
nifedipine and the HMG CoA reductase inhibitors cerivasatin and fluvastatin (Fisslthaler 
et al., 2003) that stimulate an increase in CYP2C expression (Fisslthaler et al., 2000a) 
and might therefore interfere with other treatments given at the same time.  Another 
important aspect when looking at the role of altered EET levels in cardiovascular 
diseases is the sEH, the enzyme that metabolizes EETs to the less biologically active 
DHETs.  Blockade of sEH leads to increased endogenous EET levels.  In recent years 
there has been considerable interest in sEH as a potential target for antihypertensive 
therapy as specific inhibitors have been shown to be very effective at preventing as well 
as reversing the hypertensive effects of angiotensin II (Imig, 2005; Jung et al., 2005).  In Discussion 
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this context sEH inhibition could potentially result in increased expression of for 
example EphB4 and this might explain side effects that occur during treatment. 
Over the course of the present investigation it was possible to further clarify the 
molecular mechanisms involved in the CYP2C-mediated regulation of vascular 
homeostasis.  At least two additional signalling molecules that have been reported to 
play an important role in the regulation of angiogenesis have been identified as being 
crucial for the angiogenic answer mediated by CYP2C i.e., VEGF and  EphB4. 
Identification of the latter pathways as being modulated by altered CYP2C activity 
significally expands and complements the current understanding of the mechanisms 
involved in EET-induced angiogenesis and emphasises the central importance of 
CYP2C in the regulation of vascular tone and homeostasis. 
 Summary 
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5. Summary   
 
Cytochrome P450 epoxygenases of the 2C family (CYP2C) are highly expressed in the 
endothelium and metabolize arachidonic acid to different regioisomers of 
epoxyeicosatrienoic acids (EET).  They have a number of roles in the regulation of 
vascular tone and homeostasis by activating different signal transduction pathways and 
have recently been reported to be involved in proliferation and angiogenesis.  However, 
the exact mechanisms by which epoxygenases regulate angiogenesis are still unclear.  
In particular the involvement of important endothelial growth factors and to what extent 
they are involved in CYP2C-mediated vessel formation needs to be elucidated.   
Therefore, the initial aim of the present study was to characterize the relevance of major 
signalling molecules that are involved in angiogenesis and to investigate possible 
signalling pathways involved. 
Initially the effect of CYP2C9 overexpression on expression levels of EphB4, a tyrosine 
kinase that plays a role in a number of developmental processes, was investigated.  
EphB4 protein expression was increased in CYP2C9 overexpressing cells without any 
effects on expression levels of its ligand ephrinB2.  The effect was induced by the 
metabolite 11,12-EET and was abolished by the CYP epoxygenase inhibitor MSPPOH 
as well as by the PI3K inhibitor LY 294002 and simultaneous transfection with a 
dominant negative mutant of Akt.  Moreover, endogenous EphB4 expression was down-
regulated in cells transfected with CYP2C9 antisense oligonucleotides. To clarify 
whether EphB4 is a critical determinant of CYP2C9-induced angiogenesis, endothelial 
cell sprouting was assessed using a collagen gel-based in vitro angiogenesis assay. 
Following transfection with EphB4 antisense or scrambled oligonucleotides, capillary-
like structures were clearly present after 24 hours in cells overexpressing CYP2C9, 
while EphB4 downregulation abolished CYP2C9-induced sprouting.   
In addition stimulation of human umbilical vein endothelial cells with VEGF resulted in 
an increase in CYP2C expression and a subsequent increase of 11,12-EET production; 
an effect that was abolished by the CYP epoxygenases inhibitor MSPPOH as well as 
when cells were infected with a dominant negative mutant of AMPK.  Furthermore, it 
was shown that CYP2C is involved in VEGF-induced tube formation while there was no 
effect of the EET-antagonist 14,15-EEZE when cells were treated with bFGF.  Summary 
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Moreover, this study aimed at specifying the relevance of the in vitro findings for the 
angiogenic process and confirming the role of those findings in vivo.  One crucial step in 
vessel formation is proliferation and differentiation of endothelial cells to form vascular 
tubes.  In vivo 11,12-EET treatment increased EphB4 expression in mesenteric arteries 
as well as in Matrigel plugs; an effect that was abolished when plugs were impregnated 
at the same time with small interfering RNA (siRNA) for EphB4.  Furthermore, 
impregnation of Matrigel plugs with VEGF resulted in endothelial cell and smooth 
muscle cell recruitment into a Matrigel plug and this effect was mediated by CYP2C9-
derived EETs as it was prevented by 14,15-EEZE.   
When infiltration of EET impregnated plugs with endothelial cells and pericytes/smooth 
muscle cells in vivo was compared to the effects seen in VEGF treated plugs, it was 
apparent that only EET treatment resulted in the formation of tube like structures that 
were covered by smooth muscle cells.  Therefore, the final aim of the study was to 
further define the consequences of EET signalling in vivo as well as to characterize its 
physiological relevance.  This hypothesis could be assessed by isolectin injection 
through the tail-vein where isolectin was taken up only by the EET-impregnated plug.  
Moreover ultrasound measurements revealed accumulation of contrast agent in EET 
impregnated plugs compared to control plugs. 
Taken together our findings emphasize the in vitro as well as in vivo relevance of 
CYP2C and CYP-derived EETs in angiogenesis and vascular maturation.  CYP2C plays 
a crucial role in the vessel formation process by modulating the effects mediated by two 
important control elements of the angiogenic response, namely VEGF and EphB4.  It 
was shown that CYP2C-derived EETs play a critical role in modulating the activity of 
these growth factor receptors and failure to do so results in defective signalling.   
Consequently, CYP2C-derived EETs not only participate as second messengers in the 
angiogenic response, but have the potential to influence much more than angiogenesis 
by enhancing smooth muscle cell/pericyte recruitment to endothelial cell tubes to 
promote vascular maturation.  However the exact steps resulting in EET-mediated 
pericyte/smooth muscle cell recruitment still need to be elucidated.   
 Zusammenfassung 
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6. Zusammenfassung 
 
Im nativen Endothel exprimierte Cytochrom P450 Epoxygenasen der 2C Familie 
(CYP2C) synthetisieren aus Arachidonsäure verschiedene Regioisomere der 
Epoxyeicosatriensäure (5,6-; 8,9-; 11,12- und 14,15 EET), welche eine wichtige Rolle 
bei der Regulation des vaskulären Tonus und der Homöostase spielen.  Desweitern 
sind EETs wichtige intrazelluläre Signaltransduktionsmoleküle, die eine Reihe von 
Funktionen erfüllen, die über die Regulation des Membranpotentials und ihre Rolle als 
‚endothelium derived hyperpolarizing factor’ hinausgehen.  Hierbei ist die genaue 
Wirkung der CYP-Metaboliten nicht nur abhängig von den daran beteiligten 
Regioisomeren, sondern auch von Gewebetyp und Spezies.  Besonders im Endothel 
aktivieren vor allem 11,12- und 14,15-EET eine Reihe von Tyrosinkinasen- und 
phosphatasen wie die „p38 mitogen-activated protein (MAP) kinase“, die „extracellular 
regulated protein kinase“ 1 und 2 (ERK1/2) und die MAP Kinase Phosphatase. 
Andererseits hemmen sie jedoch auch eine Reihe von Signaltransduktionsmolekülen 
wie z.B. die c-Jun N-terminal Kinase.  Obwohl schon  beschrieben wurde, dass Enzyme 
der CYP2C Familie an Prozessen der Proliferation und Angiogenese beteiligt sind, 
indem sie zum Beispiel den „epidermal growth factor (EGF)“ transaktivieren, ist der 
genaue molekulare Mechanismus ihrer Wirkung noch weitestgehend ungeklärt.   
Deswegen war das primäre Ziel der vorliegenden Arbeit die Identifizierung von 
Signaltransduktionsmolekülen, die an der CYP-induzierten Angiogenese beteiligt sind, 
sowie die nachfolgende Charakterisierung möglicher darin involvierter 
Signaltransduktionskaskaden. 
Zunächst wurde der Einfluss von CYP2C9 auf die Expression von EphB4 untersucht.  
EphB4 gehört zur Familie der erst kürzlich identifizierten Gruppe von Eph Rezeptoren, 
die eine entscheidende Rolle in der vaskulären Entwicklung und Angiogenese spielen.  
Eph Rezeptoren sind eine Gruppe von Tyrosinkinasen, die ursprünglich als 
Leitmoleküle bei der Führung von Nerven identifiziert wurden, aber auch entscheidend 
für verschiedene Prozesse der Angiogenese sind, wie z.B. die Ausbildung juxtakriner 
Zell-Zell Kontakte, die Adhäsion an extrazelluläre Matrices, die Zellmigration und –
proliferation.  Im Gegensatz zu anderen Rezeptortyrosinkinasen, die an lösliche 
Liganden binden, interagieren Eph Rezeptoren mit an die Zelloberfläche gebundenen 
Ephrin Liganden. Diese sind entweder über einen Glycosylphosphatidylinositolanker Zusammenfassung 
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oder über eine transmembrane Domäne mit der Zellmembran verbunden.  Eph 
Rezeptoren können in zwei Unterklassen,  A und B , unterteilt werden, wobei für die 
vaskuläre Entwicklung der Rezeptor EphB4 der wichtigste Vertreter ist.  Es konnte zum 
Beispiel unter anderem gezeigt werden, dass Mausmutanten, denen EphB4 fehlt, einen 
Phänotyp mit gestörter Gefäßbildung und einer verfrühten embryonalen Letalität 
aufweisen.  Eine weitere Besonderheit dieser Signalmoleküle besteht darin, dass Eph-
ephrin Signalübermittlung bidirektional, also sowohl durch Ligand als auch Rezeptor,  
erfolgt. 
Obwohl CYP2C Protein im nativen Endothel in ausreichender Menge nachweisbar ist, 
nimmt die Expression sowohl von mRNA als auch Protein nach Zellisolation rapide ab 
und kann bereits  in der zweiten Passage bei Kultivierung nicht mehr nachgewiesen 
werden.  Folglich muss bei der Untersuchung von Effekten und der biologischen 
Bedeutung der von CYP2C-stammenden EETs in vitro das Protein entweder durch 
pharmakologische oder hämodynamische Stimuli (z.B. Schubspannung), durch Hypoxie 
oder durch den Einsatz von adenoviralen Konstrukten (CYP-Überexpression) 
hochreguliert werden.  Um einen Zusammenhang zwischen der Expression der 
Tyrosinkinase EphB4 und CYP2C9 zu untersuchen, wurden daher humane 
Nabelschnurzellen entweder mit einem Kontrollvirus (CYP2C antisense) oder einem 
CYP2C9-kodierenden Adenovirus infiziert.  In CYP2C9-überexprimierenden Zellen war 
die EphB4-Proteinexpression bereits nach 24 Stunden im Vergleich zur Kontrolle erhöht 
ohne einen Einfluss auf die Expression des Liganden ephrinB2 zu haben.  Dieser Effekt 
konnte einer erhöhten CYP Epoxygenaseaktivität zugeschrieben und durch den CYP 
Epoxygenaseinhibitor MSPPOH verhindert werden.  Eine Phosphorylierung und damit 
Aktivierung des Rezeptors durch erhöhte CYP2C-Spiegel konnte ebenfalls 
nachgewiesen werden, denn die CYP2C-Überexpression resultierte in der 
Tyrosinphosphorylierung von EphB4.  Desweiteren konnte gezeigt werden, dass dieser 
Effekt direkt EET-vermittelt ist und nicht durch einen der anderen CYP-Metaboliten oder 
durch reaktive Sauerstoffspezies verursacht wurde, denn auch die direkte Gabe von 
11,12-EET führte zu erhöhter EphB4 Expression. 
Folglich konnte eine Bedeutung von CYP2C in der EphB4-vermittelten 
Signaltransduktion nachgewiesen werden, aber die genaue Bedeutung von EphB4  in 
der CYP2C-induzierten Bildung von Gefäßen war noch nicht erörtert.  Ein 
entscheidender erster Schritt für die Blutgefäßbildung ist die Proliferation und 
Differenzierung von Endothelzellen, was zur Bildung von vaskulären röhrenartigen Zusammenfassung 
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Gebilden (engl. „Tubes“) führt.  Dabei muss vor der Migration von Endothelzellen erst 
die umliegende Matrix, die vor allem aus Kollagen, Elastin, Fibronektin und 
Proteoglykan besteht, abgebaut werden.  Die hierbei ablaufenden Vorgänge können in 
vitro in zwei- oder dreidimensionalen Angiogenese-„Assays“ untersucht werden, wobei 
die in vitro verwandten Wachstumsmatrices, wie z.B. Kollagen, Matrigel oder Fibrin, den 
in vivo Gegebenheiten nachempfunden sind,.  Um den Einfluss von EphB4 auf die 
CYP2C-vermittelte Angiogenese zu untersuchen, wurde ein auf Kollagen basierender 
dreidimensionaler Sprossungs-(engl. „sprouting“)„Assay“ verwendet.  Um hierbei die 
Expression von EphB4 zu verhindern, wurden Endothelzellen zunächst mit EphB4 
antisense Oligonukleotiden bzw. mit Kontrolloligonukleotiden (EphB4 scrambled) 
behandelt.  Danach wurden Endothelzellspheroide gebildet und das Ausmaß der   
Sprossung mikroskopisch analysiert.  Es zeigte sich eine verminderte Sprossung von 
Endothelzellspheroiden unter Einfluss von EphB4-antisense Oligonukleotiden im 
Vergleich zu Spheroiden, die vorher mit „scrambled“ Oligonukleotiden behandelt 
wurden. 
Bisher ist noch sehr wenig über die Signaltransduktionswege, die zur Expression von 
EphB4 führen, bekannt.  PI3K kann durch eine Reihe von extrazellulären Signalen 
aktiviert werden und ist an vielen zellulären Vorgängen, wie z.B. Zellproliferation, 
Zellüberleben, Proteinsynthese und Tumorwachstum, beteiligt.  Da beschrieben ist, 
dass EETs, insbesondere 11,12-und 14,15-EETs, den PI3K/Akt Signaltransduktionsweg 
in Endothelzellen aktivierten, wurde der Einfluss dieses Signalweges auf die CYP2C9-
vermittelte EphB4 Expression und mögliche biologische Konsequenzen untersucht.   
Eine Hemmung der PI3K mit dem spezifischen Inhibitor LY 294002 führte sowohl zu 
einer geringeren Aktivierung des EphB4 Promotors in CYP2C-überexpremierenden 
Zellen als auch zu einer verminderten EphB4 Proteinexpression.  Auch die gleichzeitige 
Infektion mit einer dominant negativen Akt-Mutante hob die erhöhte EphB4 Expression 
in CYP2C9-überexprimierten Zellen auf. 
Um nun aufzuklären, ob die in vitro Befunde auch eine in vivo Relevanz aufweisen, 
wurde zunächst der Einfluss von EETs im Matrigel-Plug-„Assay“ untersucht.  Die 
Imprägnierung solcher Plugs mit 11,12-EET führte zu einem erhöhten Einwandern von 
Endothelzellen und Perizyten/glatten Muskelzellen in das Matrigel im Vergleich zu 
Kontroll-Plugs.  Dies konnte durch den gleichzeitigen Einschluss von siRNA gegen 
EphB4 verhindert werden.  Unter  EET-Einfluss bildeten sich im Plug röhrenförmigen 
Strukturen aus, die mit Perizyten/glatten Muskelzellen umkleidet waren.  Außerdem Zusammenfassung 
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konnte in diesen röhrenförmigen Strukturen nur nach Behandlung mit EET, nicht aber in 
der Kontrolle, die Expression von EphB4 eindeutig nachgewiesen werden. 
Desweiteren sollte ein Zusammenhang zwischen „vascular endothelial growth 
factor“(VEGF)- und CYP-vermittelten Signaltransduktionswegen untersucht werden.   
Die Familie der VEGFs ist eine sehr heterogene Gruppe mit einer Vielzahl von 
Untergruppen. VEGF ist als einer der Schlüsselsubstanzen bei der Regulation von 
sowohl physiologischer als auch pathologischer Angiogenese von entscheidender 
Bedeutung.  Da bekannt ist, dass die Expression von VEGF unter hypoxischen 
Bedingungen zunimmt und, dass CYP2C an der hypoxievermittelten Angiogenese 
beteiligt ist, postulierten wir einen möglichen Zusammenhang zwischen VEGF- und 
CYP-Expression. 
Die Stimulation von Endothelzellen humaner Nabelschnurvenen mit VEGF führte zu 
einer Steigerung der CYP2C-Expression und konnte durch den Epoxygenaseinhibitor 
MSPPOH gehemmt werden.  Außerdem kam es unter VEGF-Einfluss zur vermehrten 
11,12-EET Bildung.  VEGF reguliert die CYP2C9 Expression auch auf 
Transkriptionsebene, denn Stimulation mit VEGF führte zu einer Erhöhung der CYP2C 
Promoteraktivität in VEGF-Rezeptor exprimierenden Endothelzellen, nicht aber in Zellen 
ohne VEGF-Rezeptor.   
Die AMPK-aktivierte Proteinkinase spielt eine bedeutende Rolle bei der Regulation des 
Zellstoffwechsels unter hypoxischen Bedingungen und bei der Muskelkontraktion.  Da 
sie außerdem sowohl an der Regulation der Hypoxie- und VEGF-vermittelten 
Angiogenese, als auch an der durch Phenobarbital ausgelösten Induktion von CYP 
beteiligt ist, wurde ein Zusammenhang zwischen AMPK und der VEGF-vermittelten 
CYP2C Expression untersucht.  Es konnte gezeigt werden, dass eine Stimulation mit 
VEGF zu einer schnellen Phosphorylierung der AMPK führte.  Wurden Endothezellen 
aber gleichzeitig mit einer dominant negativen Mutante der AMPK transfiziert, war 
sowohl die VEGF-vermittelte CYP2C-Expression als auch die Phosphorylierung der 
AMPK aufgehoben. 
Darüber hinaus sollte auch hier die physiologische Bedeutung dieser in vitro Befunde in 
vivo weiter konkretisiert werden und die Relevanz für den Angiogeneseprozess erörtert 
werden.  In einem Fibrin-basierten Angiogenese-„Assay“ konnte gezeigt werden, dass 
CYP2C an der VEGF-, nicht aber an der bFGF-vermittelten Ausbildung von 
röhrenförmigen Strukturen beteiligt ist, da der EET-Antagonist 14,15-EEZE 
beispielsweise in bFGF-behandelten Zellen keinerlei Effekt hatte.  Desweiteren Zusammenfassung 
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verhinderte die gleichzeitige Transfektion der Endothelzellen mit einer dominant 
negativen AMPK-Mutante die Ausbildung dieser Strukturen.  In vivo führte die 
Imprägnierung eines Matrigel-Plugs mit sowohl VEGF als auch bFGF zwar zur 
Rekrutierung von Endothelzellen (und in geringerem Ausmaß auch zur Rekrutierung 
von glatten Muskelzellen bzw. Perizyten), aber diese Rekrutierung konnte nur in den 
VEGF imprägnierten Plugs durch den spezifischen EET-Antagonisten 14,15-EEZE 
verhindert werden.   Außerdem führte gleichzeitige Behandlung des Plugs mit der 
dominant negativen Mutante der AMPK zur deutlich verminderten Einwanderung von 
Endothelzellen in das Matrigel. 
In der vorliegenden Arbeit wurde auch der Einfluss von EETs auf die Reifung von 
Gefäßen untersucht. Dabei zeigte sich, dass die  Einwanderung von Endothelzellen und 
Pericyten/glatten Muskelzellen in vivo in einen EET-imprägnierten Plug vergleichbar war 
mit der Einwanderung in VEGF-behandelte Plugs.   Allerdings führte nur die EET-
Behandlung zur Ausbildung von vaskulären „Tubes“, die auch mit glatten Muskelzellen 
ausgekleidet waren.  Um zu klären, ob diese röhrenartigen Strukturen auch perfundiert 
wurden, wurde kurz vor Dislokation der Wirbelsäure Isolektin in die Schwanzvene der 
Mäuse injiziert.  Nur durch EET-imprägnierte Plugs, nicht aber durch die mit VEGF 
imprägnierten Plugs, wurde Isolektin aufgenommen.  Um die Funktionalität der „Tubes“ 
weiterhin zu bestätigen, wurden die Matrigel Plugs in der lebenden Maus 
Ultraschallmessungen unterzogen.  Hierbei konnte nur ein erhöhtes Anfluten von 
Kontrastmittel im EET-behandelten Plug, nicht aber  im Kontrollplug gemessen werden, 
was ein weiterer Hinweis für die Ausbildung von perfundierten, funktionsfähigen 
Gefäßstrukturen ist. 
Zusammenfassend lässt sich sagen, dass EETs über die Modulation zweier wichtiger 
Stellglieder der angiogenen Antwort, nämlich VEGF und EphB4, eine Rolle bei der 
Regulation von Rezeptoren und Signaltransduktionsmolekülen spielen, die essentiell für 
die normale Blutgefässentwicklung und Gefäßreifung sind.  Die von CYP2C-
stammenden EETs sind nicht nur als sekundäre Botenstoff an der angiogenen Antwort, 
die durch eine Vielzahl von Faktoren ausgelöst wird, beteiligt, sondern haben zudem 
das Potential sowohl Endothelzellen als auch Perizyten/glatte Muskelzellen zu 
rekrutieren, und leisten so ein entscheidender Beitrag zum vaskulären Reifungsprozess. 
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8. Abbreviations 
 
AMPK     AMP activated protein kinase 
Ang-1    Angiotensin  1 
BSA    Bovine  serum  albumine 
Ca
2+    Calcium 
CYP    Cytochrome  P450 
DHET     Dihydroxyeicosatrienoic acids  
ECM    Extracellular  matrix 
EDHF     Endothelium-derived hyperpolarizing factor 
EET      Epoxyeicosatrienoic  acid 
EEZE    14,15-Epoxyeicosa-5(Z)-enoic  acid 
EGF       Epidermal growth factor  
FCS      Fetal  calf  serum 
bFGF     Basic fibroblast growth factor  
Flk-1      Fetal liver kinase receptor 
Flt-1    Fms-like  tyrosine  kinase 
HETE     Hydroxyeicosatetranoic  acids 
HGF    Hepatocyte  growth  factor 
HPLC     High pressure liquid chromatography 
HUVEC   Human  umbilical vein endothelial cells 
Mic    Miconazole 
MLEC     Mouse lung endothelial cells 
MS    Mass  spectronomy 
MSPPOH   N-methanesulfonyl-6-(2-proparyloxyphenyl)hexanamide 
NADPH   Nicotinamidadeninnucleptide phosphate 
NO    Nitric  oxide 
PBS    Phosphate  buffered  saline 
PAEC     Porcine aortic endothelial cells 
PCR      Polymerase chain reaction  
PDGF    Platelet-derived  growth  factor 
PECAM-1    Platelet and endothelial cell adhesion molecule-1 Abbreviations 
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PIGF    Placental  growth  factor 
PGI2    Prostacyclin 
PI3K    Phosphatidylinositol-3 kinase 
PKA    Protein  kinase  A 
RTK    Receptor  Tyrosine  Kinase 
SDS      Sodium dodecyl sulphate  
SMC    Smooth  muscle  cells 
TGF-β    Transforming  growth  factor  β 
TRIS    Tris-hydroxymethyl-aminomethan 
VEGF     Vascular endothelium growth factor 
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